Document:

Exhibit 4.2

 

Execution Version

 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT

 

THIS AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT (this “Agreement”), is made as of the 21st day of December, 2020, by and among
Immuneering Corporation, a Delaware corporation (the “Company”), and each of the investors listed on Schedule
A hereto, each of which is referred to in this Agreement as an “Investor” and any Additional
Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9
hereof.

 

RECITALS

 

WHEREAS, certain of
the Investors (the “Existing Investors”) hold shares of the Company’s Series A Preferred Stock, par value $0.001
per share (“Series A Preferred Stock”) and/or shares of Common Stock issued upon conversion thereof and possess registration
rights, information rights, rights of first offer and other rights pursuant to that certain Investors’ Rights Agreement dated as
of September 20, 2020, by and among the Company and such Existing Investors (the “Prior Agreement”);

 

WHEREAS, the Existing Investors
are holders of a majority of the Registrable Securities of the Company (as defined in the Prior Agreement), and desire to amend and restate
the Prior Agreement in its entirety and to accept the rights created pursuant to this Agreement in lieu of the rights granted to them
under the Prior Agreement; and

 

WHEREAS, the Company
and certain of the Investors are parties to that certain Series B Preferred Stock Purchase Agreement of even date herewith by and among
the Company and such Investors (the “Purchase Agreement”), under which certain of the Company’s and such Investors’
obligations are conditioned upon the execution and delivery of this Agreement by such Investors, Existing Investors holding a majority
of the Registrable Securities (as defined in the Prior Agreement) and the Company.

 

1.             
NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Company and the Investors, including the Existing Investors, each hereby agree that the Prior Agreement
shall be amended and restated in its entirety as set forth herein, and the parties to this Agreement, intending to be legally bound,
hereby further agree as follows:Definitions. For purposes of this Agreement:

 

1.1              
“Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls,
is controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer,
director or trustee of such Person, or any venture capital fund, other investment fund or registered investment company now or hereafter
existing that is controlled by one or more general partners, managing members or investment adviser of, or shares the same management
company or investment adviser with, such Person.

 

1.2               
“BlackRock” means BlackRock Health Sciences Trust II.

 

     

     

    

 

1.3               
 “Board of Directors” means the board of directors of the Company.

 

1.4               
“Boxcar” means Boxcar PMJ, LLC.

 

1.5               
 “Certificate of Incorporation” means the Company’s Third Amended and Restated Certificate of Incorporation,
as amended and/or restated from time to time.

 

1.6               
 “Common Stock” means shares of the Company’s common stock, par value $0.001 per share.

 

1.7               
“Competitor” means a Person engaged, directly or indirectly (including through any partnership, limited liability
company, corporation, joint venture or similar arrangement (whether now existing or formed hereafter)), in biopharmaceutical research
and development and drug discovery and development, but shall not include (i) any financial investment firm or collective investment
vehicle that, together with its Affiliates, holds less than twenty percent (25)% of the outstanding equity of any Competitor, (ii) Boxcar
or any of its Affiliates, (iii) Cormorant or any of its Affiliates, (iv) Surveyor or any of its Affiliates, (v) Rock Springs or any of
its Affiliates, (vi) BlackRock or any of its Affiliates, (vii) T. Rowe Price or any of its Affiliates, (viii) LYFE Capital or any of
its Affiliates or (ix) Perceptive or any of its Affiliates.

 

1.8               
“Cormorant” means, collectively, Cormorant Private Healthcare Fund III, LP, Cormorant Global Healthcare Master
Fund, LP and CRMA SPV, LP.

 

1.9               
“Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto may become
subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or
any action in respect thereof) arises out of or is based upon: (i) any untrue statement or alleged untrue statement of a material fact
contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or
any amendments or supplements thereto; (ii) an omission or alleged omission to state therein a material fact required to be stated therein,
or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the
indemnifying party (or any of its agents or Affiliates)
of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the
Exchange Act, or any state securities law.

 

1.10             
“Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for
(in each case, directly or indirectly), Common Stock, including
options and warrants.

 

1.11            
“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
thereunder.

 

    2 

     

    

 

1.12             
 “Excluded Registration”
means (i) a registration relating to the sale or grant of securities to employees of the Company or a subsidiary pursuant to a stock
option, stock purchase, equity incentive or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a registration
on any form that does not include substantially the same information as would be required to be included in a registration statement
covering the sale of the Registrable Securities; or (iv) a registration in which the only Common Stock being registered is Common Stock
issuable upon conversion of debt securities that are also being registered.

 

1.13            
“FOIA Party” means a Person that, in the reasonable determination of the Board of Directors, may be subject
to, and thereby required to disclose non-public information furnished by or relating to the Company under, the Freedom of Information
Act, 5 U.S.C. 552 (“FOIA”), any state public records access law, any state or other jurisdiction’s laws similar
in intent or effect to FOIA, or any other similar statutory or regulatory requirement.

 

1.14            
“Form
S-1” means such form under the Securities Act as in effect on the date hereof or any
successor registration form under the Securities Act subsequently adopted by the SEC.

 

1.15            
“Form S-3” means such form under the Securities Act as in effect on the date hereof or any registration
form under the Securities Act subsequently adopted by the SEC that permits forward incorporation of substantial information by reference
to other documents filed by the Company with the SEC.

 

1.16             
“GAAP” means generally accepted accounting principles in the United States as in effect from time to time.

 

1.17             
“Holder” means any holder of Registrable Securities who is a party to this Agreement.

 

1.18            
“Immediate
Family Member” means a child, stepchild,
grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law,
or sister-in-law, including, adoptive relationships, of a natural
person referred to herein.

 

1.19             
“Initiating Holders” means, collectively, Holders who properly initiate a registration request under this Agreement.

 

1.20             
“IPO” means the Company’s
first underwritten public offering of its Common Stock under the Securities Act.

 

1.21             
“Key
Employee” shall have the meaning set forth in the Purchase Agreement.

 

1.22             
“LYFE Capital” means LYFE Capital Fund III (Phoenix), L.P.

 

    3 

     

    

 

1.23            
 “Major Investor” means any Investor that individually or together with such Investor’s Affiliates, holds
at least 143,022 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization
or reclassification effected after the date hereof) and each Person to whom any of the rights of any such Investor are assigned pursuant
to Section 6.1.

 

1.24            
“New Securities” means, collectively, equity securities of the Company, whether or not currently authorized,
as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become,
convertible or exchangeable into or exercisable for such equity securities.

 

1.25             
“Perceptive” means Perceptive
Life Sciences Master Fund, Ltd.

 

1.26             
“Person” means any individual,
corporation, partnership, trust, limited liability company, association or other entity.

 

1.27             
“Preferred Director” shall have the meaning set forth in the Certificate of Incorporation.

 

1.28             
“Preferred Stock” means the Series A Preferred Stock and the Series B Preferred Stock.

 

1.29            
“Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of the Preferred Stock,
excluding any Common Stock issued upon conversion of the Series B Preferred Stock pursuant to the “Special Mandatory Conversion”
provisions of the Certificate of Incorporation; (ii) any Common Stock,
or any Common Stock issued or issuable (directly or indirectly)
upon conversion and/or exercise of any other
securities of the Company, acquired by the Investors after
the date hereof; and (iii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security
that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in
clauses (i) and (ii) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction
in which the applicable rights under this
Agreement are not assigned pursuant to Subsection 6.1,
and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Subsection
2.13 of this Agreement.

 

1.30             
“Registrable Securities then outstanding” means the number of shares determined by adding the number
of shares of outstanding Common Stock that are Registrable Securities
and the number of shares of Common Stock issuable (directly
or indirectly) pursuant to then exercisable and/or convertible
securities that are Registrable Securities.

 

1.31            
“Restricted Securities” means the securities of the Company required to be notated with the legend set forth
in Subsection 2.12(b) hereof.

 

1.32             
“Rock Springs” means, collectively, Rock Springs Capital Master Fund LP and Four Pines Master Fund LP.

 

    4 

     

    

 

1.33            
 “SEC” means the Securities and Exchange Commission.

 

1.34            
“SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act.

 

1.35            
“SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act.

 

1.36            
“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

1.37            
“Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable
to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for
the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Subsection 2.6.

 

1.38            
“Series B Preferred Stock” means shares of the Company’s Series B Preferred Stock, par value $0.001 per
share.

 

1.39            
“Surveyor” means Citadel Multi-Strategy Equities Master Fund Ltd.

 

1.40            
“T. Rowe Price” means, collectively, T. Rowe Price Health Sciences Fund, Inc., TD Mutual Funds – TD Health
Sciences Fund and T. Rowe Price Health Sciences Portfolio.

 

2.                 
Registration Rights. The Company covenants and agrees as follows:

 

2.1               
Demand Registration.

 

(a)             
Form S-1 Demand. If at any time after the earlier
of (i) five (5) years after the date of this Agreement or (ii) one hundred eighty (180) days after the effective date of the registration
statement for the IPO, the Company receives a request from Holders of a majority of the Registrable Securities then outstanding that
the Company file a Form
S-1 registration statement having an anticipated aggregate offering
price, net of Selling Expenses, of at least $15 million, then the Company shall (x) within ten (10) days after the date such request
is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon
as practicable, and in any event within sixty (60) days after the date such request is given by the Initiating Holders, file a Form
S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating
Holders requested to be registered and any
additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by
each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the
limitations of Subsections 2.1(c) and 2.3.

 

(b)            
Form S-3 Demand. If at any time when it is eligible to
use a Form S-3 registration statement, the Company receives a request from Holders of at least twenty percent (20%) of the Registrable
Securities then outstanding that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities
of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $5 million, then the Company shall
(i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders;
and (ii) as soon as practicable, and in any event within forty-five (45) days after the date such request is given by the Initiating
Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included
in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of
the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3.

 

    5 

     

    

 

(c)             
Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this
Subsection 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of
the Board of Directors it would be materially detrimental to the Company and its stockholders for such registration statement to either
become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because
such action would (i) materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving
the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving
as confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company
shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness
thereof shall be tolled correspondingly, for a period of not more than sixty (60) days after the request of the Initiating Holders is
given; provided, however, that the Company may not invoke this right more than once in any twelve (12) month period;
and provided further that the Company shall not register any securities for its own account or that of any other stockholder
during such sixty (60) day period other than an Excluded Registration.

 

(d)            
The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(a)(i)
during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on
a date that is one hundred eighty (180) days after the effective date of, a Company-initiated registration, provided that the
Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective;
(ii) after the Company has effected one registration pursuant to Subsection
2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately
registered on Form S-3 pursuant to a request made pursuant to Subsection 2.1 (b).
The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1
(b) (i) during the period that is thirty (30) days before the Company’s
good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated
registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration
statement to become effective; or (ii) if the Company has effected two registrations pursuant to Subsection 2.1 (b)
within the twelve (12) month period immediately preceding the date
of such request. A registration shall not be counted as “effected” for purposes of this Subsection 2.1(d) until
such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their
request for such registration, elect not to pay the registration expenses therefor, and
forfeit their right to one demand registration statement pursuant to Subsection 2.6,
in which case such withdrawn registration statement shall be counted as “effected” for purposes of this Subsection 2.1(d);
provided, that if such withdrawal is during a period the Company has deferred taking action pursuant to Subsection 2.1(c),
then the Initiating Holders may withdraw their request for registration and such registration will not be counted as “effected”
for purposes of this Subsection 2.1(d).

 

    6 

     

    

 

2.2              
Company Registration. If the Company proposes to register (including, for this purpose, a registration effected by the
Company for stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering
of such securities solely for cash (other than in an Excluded Registration), the Company shall, at such time, promptly give each Holder
notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company,
the Company shall, subject to the provisions of Subsection 2.3, cause to be registered all of the Registrable Securities that
each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration
initiated by it under this Subsection 2.2 before the effective date of such registration, whether or not any Holder has elected
to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall
be borne by the Company in accordance with Subsection 2.6.

 

2.3               
Underwriting Requirements.

 

(a)             
If, pursuant to Subsection 2.1, the Initiating Holders
intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company
as a part of their request made pursuant to Subsection 2.1,
and the Company shall include such information in the Demand Notice. The underwriter(s)
will be selected by the Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such
event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such
Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting
to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the
Company as provided in Subsection 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected
for such underwriting. Notwithstanding any other provision of this Subsection 2.3,
if the underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of
shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would be
underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among
such Holders of Registrable Securities, including the Initiating
Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder or
in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the
number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities
are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the
Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares.

 

    7 

     

    

 

(b)            
 In connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to Subsection
2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the
Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity
as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number
of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities
to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success
of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable
Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering.
If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering,
then the Registrable Securities that are included in such offering shall be allocated
among the selling Holders in proportion (as nearly as practicable
to) the number of Registrable Securities owned by each
selling Holder or in such other proportions as shall mutually
be agreed to by all such selling Holders. To facilitate the allocation
of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder
to the nearest one hundred (100) shares. Notwithstanding the foregoing, in no event shall (i) the
number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by
the Company) are first entirely excluded from the offering, or (ii) the number of Registrable Securities included in the offering
be reduced below twenty-five percent (25%) of the total number of securities included in such offering, unless such offering is the IPO,
in which case the selling Holders may be excluded further if the underwriters make the determination described above and no other stockholder’s
securities are included in such offering. For purposes of the provision in this Subsection 2.3 (b) concerning apportionment, for
any selling Holder that is a partnership, limited liability company,
or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates
and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any
of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such
 “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such
 “selling Holder,” as defined in this sentence.

 

2.4              
Obligations of the Company. Whenever required under this Section 2 to effect the registration of any Registrable
Securities, the Company shall, as expeditiously as reasonably possible:

 

(a)             
prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable
Securities registered thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) days or,
if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that
such one hundred twenty (120) day period shall be extended for a period of time equal to the period the Holder refrains, at the request
of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration;

 

    8 

     

    

 

(b)             
prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection
with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities
covered by such registration statement;

 

(c)             
furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the
Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable
Securities;

 

(d)             
use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such
other securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that
the Company shall not be required to qualify to do business or to file a general consent to service of process in any such states or
jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities
Act;

 

(e)             
in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual
and customary form, with the underwriter(s) of such offering;

 

(f)              
use its commercially reasonable efforts to cause all such Registrable Securities covered by such registration statement to be
listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar
securities issued by the Company are then listed;

 

(g)             
provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP
number for all such Registrable Securities, in each case not later than the effective date of such registration;

 

(h)             
promptly make available for inspection by the selling Holders, any underwriter(s)
participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained
by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties
of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably
requested by any such seller, underwriter, attorney, accountant, or agent,
in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate
due diligence in connection therewith;

 

(i)             
notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has
been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and

 

    9 

     

    

 

(j)             
 after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend
or supplement such registration statement or prospectus.

 

In addition, the Company shall
ensure that, at all times after any registration statement covering a public offering of securities of the Company under the Securities
Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading
program under Rule 10b5-1 of the Exchange Act.

 

2.5               
Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to
this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company
such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as
is reasonably required to effect the registration of such Holder’s Registrable Securities.

 

2.6               
Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings,
or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting
fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements, not to exceed $35,000, of one counsel
for the selling Holders (“Selling
Holder Counsel”), shall be borne and paid by the Company; provided,
however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Subsection
2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities
to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities
that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit
their right to one registration pursuant to Subsections 2.1(a) or 2.1(b),
as the case may be, then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one
registration pursuant to Subsections 2.1(a) or 2.1(b). All Selling Expenses relating to Registrable Securities registered
pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities
registered on their behalf.

 

2.7               
Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying
any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation
of this Section 2.

 

2.8               
Indemnification. If any Registrable Securities are included in a registration statement under this Section 2:

 

(a)             
To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members, officers,
directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the
Securities Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities
Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other
aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim
or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity
agreement contained in this Subsection 2.8 (a) shall not apply to amounts paid in settlement of any such claim
or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld,
nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance
upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or other
aforementioned Person expressly for use in connection with such registration.

 

    10 

     

    

 

(b)            
To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company,
and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company
within the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities
Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other
Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made
in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection
with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other
expenses reasonably incurred thereby in connection with investigating or defending any claim
or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity
agreement contained in this Subsection 2.8 (b) shall not apply to amounts paid in settlement of any such claim
or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld;
and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under
Subsections 2.8 (b) and 2.8(d) exceed the proceeds from the offering received
by such Holder (net of any Selling Expenses paid by such Holder),
except in the case of fraud or willful misconduct by such Holder.

 

(c)             
Promptly after receipt by an indemnified party under this Subsection 2.8 of notice of the commencement of any action (including
any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect
thereof is to be made against any indemnifying party under this Subsection 2.8,
give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in
such action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to which notice
has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however,
that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall
have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of
such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing
interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to
the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability
to the indemnified party under this Subsection 2.8, to
the extent that such failure materially prejudices the indemnifying party’s ability to defend such action. The failure to give
notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under
this Subsection 2.8.

 

    11 

     

    

 

(d)             
To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either: (i) any
party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but it
is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time
to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the
fact that this Subsection 2.8 provides for indemnification in such case, or (ii) contribution under the Securities Act may be
required on the part of any party hereto for which indemnification is provided under this Subsection 2.8,
then, and in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to
which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each
of the indemnifying party and the indemnified party in connection
with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect
any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined
by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged
omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’
relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided,
however, that, in any such case (x) no Holder will be required to contribute any amount in excess of the public offering price
of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty
of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any
Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability
pursuant to this Subsection 2.8 (d), when combined with the amounts paid or payable by such Holder pursuant to Subsection 2.8
(b), exceed the proceeds from the offering received by such Holder
(net of any Selling Expenses paid by such Holder),
except in the case of willful misconduct or fraud by such Holder.

 

(e)             
Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting
agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions
in the underwriting agreement shall control.

 

(f)             
Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the
obligations of the Company and Holders under this Subsection 2.8 shall survive the completion of any offering of Registrable Securities
in a registration under this Section 2, and otherwise shall survive the termination of this Agreement.

 

    12 

     

    

 

 

2.9         
 Reports Under Exchange Act. With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule
or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or
pursuant to a registration on Form S-3, the Company shall:

 

(a)        
make and keep available adequate current public information,
as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed
by the Company for the IPO;

 

(b)        
use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company
under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and

 

(c)        
furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to
the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at
any time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities
Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as
a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies); (ii) a copy of the
most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company; and (iii) such other
information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any
such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange
Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form).

 

2.10        
Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without
the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with
any holder or prospective holder of any securities of the Company that would allow such holder or prospective holder to include such
securities in any registration unless, under the terms of such agreement, such holder or prospective holder may include such securities
in any such registration only to the extent that the inclusion of such securities will not reduce the number of the Registrable Securities
of the Holders that are included; provided that this limitation shall not apply to Registrable Securities acquired by any additional
Investor that becomes a party to this Agreement in accordance with Subsection 6.9.

 

    13 

     

    

 

2.11        
“Market Stand-off” Agreement. Each Holder hereby agrees that it will not, without the prior written consent
of the managing underwriter, during the period commencing on the date of the final prospectus relating to the IPO
(such period not to exceed one hundred eighty (180) days), (i) lend; offer; pledge; sell; contract to sell; sell any option or
contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer
or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly
or indirectly) for Common Stock held immediately before the effective date of the registration statement for the IPO or (ii) enter
into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such
securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or
other securities, in cash, or otherwise. The foregoing provisions of this Subsection 2.11 shall apply only to the IPO, shall not
apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, or
the transfer of any shares to any trust for the direct or indirect benefit of the Holder or the immediate family of the Holder, provided
that the trustee of the trust agrees to be bound in writing by the restrictions set forth herein, and provided further that
any such transfer shall not involve a disposition for value, and shall be applicable to the Holders only if all officers, directors and
stockholders individually owning one percent (1%) or more of the Company’s outstanding Common Stock (after giving effect to conversion
into Common Stock of all outstanding Preferred Stock) are subject to the same restrictions. The underwriters in connection with
such registration are intended third-party beneficiaries of
this Subsection 2.11 and shall have the right, power and authority to enforce the provisions hereof as though they were a party
hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection
with such registration that are consistent with this Subsection 2.11 or that are necessary to give further effect thereto.
In the event that the Company or the managing underwriter waives or terminates any of the restrictions contained in this Subsection
2.11 or in a lock-up agreement with respect to the securities of any Holder, officer, director than one-percent or greater stockholder
of the Company (in any such case, the “Released Securities”), the restrictions contained in this Subsection 2.11
and in any lock-up agreements executed by the Investors shall be waived or terminated, as applicable, to the same extent and with
respect to the same percentage of securities of each Investor as the percentage of Released Securities represent with respect to the
securities held by the applicable Holder, officer, director than one-percent or greater stockholder. Notwithstanding anything herein
to the contrary, the provisions of this Subsection 2.11 shall not apply to transactions (including, without limitation, any swap,
hedge or similar agreement or arrangement) or announcements, in each case, relating to securities acquired in the IPO or securities acquired
in open market or other transactions from and after the IPO or that otherwise do not involve or relate to securities of the Company owned
by a Holder prior to the IPO.

 

2.12        
Restrictions on Transfer.

 

(a)        
The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall
not recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except
upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities
Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of Preferred Stock and the Registrable Securities
held by such Holder to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement.
Notwithstanding the foregoing, the Company shall not require any transferee of shares pursuant to an effective registration statement
or, following the IPO, SEC Rule 144 to be bound by the terms of this Agreement.

 

    14 

     

    

 

(b)        
 Each certificate, instrument, or book entry representing
(i) the Preferred Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced
in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event, shall (unless
otherwise permitted by the provisions of Subsection 2.12 (c)) be notated with a legend substantially
in the following form:

 

THE SECURITIES
REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH
REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT.

 

THE SECURITIES
REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE
WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.

 

The Holders consent to the
Company making a notation in its records and giving instructions to any transfer agent of the Restricted Securities in order to implement
the restrictions on transfer set forth in this Subsection 2.12.

 

(c)        
The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions
of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration
statement under the Securities Act covering the proposed transaction or, following the IPO, the transfer is made pursuant to SEC Rule
144, the Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each
such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably
requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall,
and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction
may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that
the proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by the
staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company
to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the
Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities
in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no
action” letter (x) in any transaction in compliance with SEC Rule
144; (y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration
or (z) in any internal transaction in which such Holder transfers Restricted Securities to an Affiliate of such Holder that is an entity
and that is ultimately controlled by the same parent company as the Holder (or is the ultimate parent company of the Holder); provided
that, in the case of clauses (y) and (z), other than in connection with a transaction in compliance with SEC Rule 144 following the
IPO, each transferee agrees in writing to be subject to the terms of this Subsection 2.12.
Notwithstanding the foregoing, the Company shall be obligated to reissue promptly unlegended certificates or book entries at the
request of any Holder thereof if the Company has completed its IPO and the Holder shall have obtained an opinion of counsel (which counsel
may be counsel to the Company) to the effect that the securities proposed to be disposed of may lawfully be so disposed of without registration,
qualification and legend, provided that the second legend listed above shall be removed only at such time as the Holder of such certificate
is no longer subject to any restrictions hereunder. Each certificate, instrument,
or book entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer
is made pursuant to SEC Rule 144 or pursuant to an effective registration
statement, the appropriate restrictive legend set forth in Subsection 2.12 (b), except that such certificate instrument, or book
entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is
not required in order to establish compliance with any provisions of the Securities Act.

 

    15 

     

    

 

2.13        
Termination of Registration Rights. The right of any Holder to request registration or inclusion of Registrable Securities
in any registration pursuant to Subsections 2.1 or 2.2 shall terminate upon the earliest
to occur of:

 

(a)        
Following the closing of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation;

 

(b)        
such time after consummation of the IPO as SEC Rule 144 or another similar exemption under the Securities Act is available for
the sale of all of such Holder’s shares without limitation
during a three-month period without registration; 

 

(c)         
the first anniversary of the IPO.

 

3.          
Information Rights.

 

3.1          
Delivery of Financial Statements. The Company shall deliver to each Major Investor, provided that the Board of Directors
has not reasonably determined that such Major Investor is a Competitor of the Company:

 

(a)        
as soon as practicable, but in any event within one hundred thirty-five (135) days after the end of each fiscal year of the Company
(i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and a comparison between (x)
the actual amounts as of and for such fiscal year and (y) the comparable amounts for the prior year and as included in the Budget (as
defined in Subsection 3.1(e)) for such year, and (iii) a statement of stockholders’ equity as of the end of such year, all
such financial statements audited and certified by independent public accountants of nationally or
regionally recognized standing selected by the Company;

 

(b)        
as soon as practicable, but in any event within thirty (30) days after the end of each of the first three (3) quarters of each
fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and a comparison between (x) the actual
amounts as of and for such fiscal quarter and (y) the comparable amounts as included in the Budget (as defined in Subsection 3.1(e))
for such quarter, and an unaudited balance sheet and a statement of stockholders’ equity as of the end of such fiscal quarter,
all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments;
and (ii) not contain all notes thereto that may be required in accordance with GAAP);

 

    16 

     

    

 

(c)        
as soon as practicable, but in any event within thirty (30) days after the end of each quarter of each fiscal year of the Company,
a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for
shares of capital stock outstanding at the end of the period, the Common Stock issuable upon conversion or exercise of any outstanding
securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of
shares of issued stock options and stock options not yet issued but reserved for issuance, if any, all in sufficient detail as to permit
the Major Investors to calculate their respective percentage equity ownership in the Company, and certified by the chief financial officer
or chief executive officer of the Company as being true, complete, and correct; provided, however, that no delivery needs to be made
under this Section 3.1(c) for as long as the Major Investor has access to the Company’s capitalization table on Carta or
another similar electronic capitalization table management platform that shows the information set forth in this Section 3.1(c);

 

(d)        
as soon as practicable, but in any event within thirty (30) days of the end of each month, an unaudited income statement
and statement of cash flows for such month, and a comparison between
(x) the actual amounts as of and for such month and (y) the comparable amounts as included in the Budget (as defined in Subsection
3.1(e)) for such month, and an unaudited balance sheet
and statement of stockholders’ equity as of the end of such
month, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments
and (ii) not contain all notes thereto that may be required in accordance with GAAP); and

 

(e)        
as soon as practicable, but in any event thirty (30) days before the end of each fiscal year, a budget and business plan for the
next fiscal year (collectively, the “Budget”), approved
by the Board of Directors (including all of the Preferred Directors) and prepared on a monthly basis, including balance sheets,
income statements, and statements of cash flow for such months and, promptly after prepared, any other budgets or revised budgets prepared
by the Company; and

 

(f)         
as soon as practicable, but in any event within twenty-five (25) days after the end of each quarter of each fiscal year of the
Company, such other information relating to the financial condition, business, scientific developments, prospects, and corporate affairs
of the Company as any Major Investor may from time to time reasonably request; provided, however, that the Company shall
not be obligated under this Subsection 3.1 to provide information (i) that the Company reasonably determines in good faith to
be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in a form acceptable to the
Company); or (ii) the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel.

 

    17 

     

    

 

If, for any period, the Company
has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial statements
delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all
such consolidated subsidiaries.

 

Notwithstanding anything else
in this Subsection 3.1 to the contrary, the Company may cease providing the information set forth in this Subsection 3.1
during the period starting with the date forty-five (45) days before the Company’s good-faith estimate of the date of filing of
a registration statement if it reasonably concludes it must do so to comply with the SEC rules applicable to such registration statement
and related offering; provided that the Company’s covenants under this Subsection 3.1 shall be reinstated
at such time as the Company is no longer actively employing its commercially reasonable efforts to cause such registration statement
to become effective.

 

3.2         
Inspection. The Company shall permit each Major Investor (provided that the Board of Directors has not reasonably
determined that such Major Investor is a Competitor of the Company), at such Major Investor’s expense, to visit and inspect the
Company’s properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts
with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investor; provided,
however, that the Company shall not be obligated pursuant to this Subsection 3.2 to provide access to any information that
it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality
agreement, in form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between
the Company and its counsel.

 

3.3          
Observer Rights. As long as Surveyor owns not less than fifty percent of the shares of the Series B Preferred Stock it
is purchasing under the Purchase Agreement (or an equivalent amount of Common Stock issued upon conversion thereof), the Company shall
invite a representative of Surveyor to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect,
shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the
same time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence
all information so provided or learned in any meeting of the Board of Directors and to not use any such information for any purpose other
than to monitor Surveyor’s investment in the Company; and provided further, that the Company reserves the right to withhold any
information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such
meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets
or a conflict of interest. Notwithstanding the foregoing, Surveyor shall not exercise its rights pursuant to this Section 3.3
unless and until the Company has confirmed in writing to Surveyor at any time after the Initial Closing (as defined in the Purchase Agreement)
that the Company does not engage in the design, fabrication, development, testing, production or manufacture of critical technologies
within the meaning of DPA (as defined in the Purchase Agreement).

 

    18 

     

    

 

3.4           Termination
of Information Rights. The covenants set forth in Subsection 3.1, Subsection 3.2 and Subsection 3.3 shall terminate and be of no
further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic
reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon the closing of a Deemed Liquidation Event, as such
term is defined in the Certificate of Incorporation, whichever event occurs first.

 

3.5           
Confidentiality. Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use
for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant
to the terms of this Agreement (including notice of the Company’s intention to file a registration statement), unless such confidential
information (a) is known or becomes known to the public in general (other than as a result of a breach of this Subsection 3.5
by such Investor), (b) is or has been independently developed or conceived by such Investor without use of the Company’s confidential
information, or (c) is or has been made known or disclosed to such Investor by a third party without a breach of any obligation of confidentiality
such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i)
to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with
monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such
prospective purchaser agrees to be bound by the provisions of this Subsection 3.5; (iii) to any Affiliate, partner, member, stockholder,
or wholly owned subsidiary of such Investor in the ordinary course of business, provided
that such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality
of such information; (iv) to the extent required in connection with any routine or periodic examination or similar process by
any regulatory or self-regulatory body or authority not specifically directed at the Company or the confidential information obtained
from the Company pursuant to the terms of the Agreement, including, without limitation, quarterly or annual reports or (v) as may otherwise
be required by law, regulation, rule, court order or subpoena, provided that , with respect to this clause (v), such Investor
promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure.

 

3.6          
Material Non-Public Information.

 

(a)        
The Company understands and acknowledges that in the regular course of Surveyor’s businesses, Surveyor and its Affiliates
will invest in companies that have issued securities that are publicly traded (each, a “Public Company”). Accordingly,
the Company covenants and agrees that before providing any material non-public information about a Public Company (“Public Company
Information”) to Surveyor or its representatives (or any of their respective Affiliates), the Company shall provide written
notice of such Public Company Information to Surveyor’s compliance officer at SCComplianceAppvl@citadel.com describing such Public
Company Information in reasonable detail. The Company shall not disclose Public Company Information to Surveyor or its representatives
(or any of their respective Affiliates) without prior written authorization from Surveyor’s compliance officer listed above.

 

    19 

     

    

 

(b)        
 The Company acknowledges and agrees that in no event shall any Investor’s confidentiality and non-use obligations hereunder
in any manner be deemed or construed as limiting such Investor or its representatives (or any of their respective Affiliates) ability
to trade any security of a Public Company.

 

4.          
Rights to Future Stock Issuances.

 

4.1          
Right of First Offer. Subject to the terms and conditions of this Subsection 4.1 and applicable securities laws,
if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor.
A Major Investor shall be entitled to apportion the right of first offer hereby granted to it in such proportions as it deems appropriate,
among (i) itself, (ii) its Affiliates and (iii) its beneficial interest holders, such as limited partners, members or
any other Person having “beneficial ownership,” as such term is defined in Rule 13d-3 promulgated under the Exchange Act,
of such Major Investor (“Investor Beneficial Owners”); provided that each such Affiliate or Investor Beneficial
Owner (x) is not a Competitor or FOIA Party, unless such party’s purchase of New Securities is otherwise consented to by the
Board of Directors and (y) agrees to enter into this Agreement and each of the Voting Agreement and Right of First Refusal and Co-Sale
Agreement of even date herewith among the Company, the Investors and the other parties named therein, as an “Investor”
under each such agreement (provided that any Competitor or FOIA Party shall not be entitled to any rights as a Major Investor
under Subsections 3.1, 3.2 and 4.1 hereof).

 

(a)         
The Company shall give notice (the “Offer Notice”) to each Major Investor, stating (i) its bona fide intention
to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which
it proposes to offer such New Securities.

 

(b)        
By notification to the Company within twenty (20) days after the Offer Notice is given, each Major Investor may elect to purchase
or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals
the proportion that the Common Stock then held by such Major Investor (including all shares of Common Stock then issuable (directly
or indirectly) upon conversion and/or exercise, as applicable,
of the Preferred Stock and any other Derivative Securities then held by such Major Investor) bears to the total Common Stock of
the Company then outstanding (assuming full conversion and/or
exercise, as applicable, of all Preferred
Stock and any other Derivative Securities then outstanding). At the expiration of such twenty (20) day period, the Company shall
promptly notify each Major Investor that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising
Investor”) of any other Major Investor’s failure to do likewise. During the ten (10) day period commencing after the
Company has given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in
addition to the number of shares specified above, up to that portion of the New Securities for which Major Investors were entitled to
subscribe but that were not subscribed for by the Major Investors which is equal to the proportion that the Common Stock issued and held,
or issuable (directly or indirectly) upon conversion and/or exercise,
as applicable, of Preferred Stock and any other Derivative Securities
then held, by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable (directly
or indirectly) upon conversion and/or exercise, as applicable,
of the Preferred Stock and any other Derivative Securities
then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this
Subsection 4.1(b) shall occur within the later of one hundred and twenty (120) days of the date that the Offer Notice is given
and the date of initial sale of New Securities pursuant to Subsection
4.1(c).

 

    20 

     

    

 

(c)        
If all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in Subsection
4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in Subsection 4.1(b),
offer and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon
terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for
the sale of the New Securities within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof,
the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the
Major Investors in accordance with this Subsection 4.1.

 

(d)        
The right of first offer in this Subsection 4.1 shall not be applicable to (i) Exempted
Securities (as defined in the Certificate of Incorporation);
(ii) shares of Common Stock issued in the IPO; and (iii) the issuance
of shares of Series B Preferred Stock pursuant to Subsection 1.3
of the Purchase Agreement.

 

4.2          
Termination. The covenants set forth in Subsection 4.1 shall terminate and be of no further force or effect (i)
immediately before the consummation of the IPO, (ii) when
the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon
the closing of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation, whichever event occurs first.

 

5.          
Additional Covenants.

 

5.1          
Insurance. The Company has obtained from financially sound and reputable insurers Directors and Officers liability insurance
in an amount and on terms and conditions satisfactory to the Board of Directors, including all of the Preferred Directors, and will use
commercially reasonable efforts to cause such insurance policies to be maintained until such time as the Board of Directors determines
that such insurance should be discontinued. The Company shall obtain, within thirty (30) days of the date hereof, from financially sound
and reputable insurers term “key-person” insurance on Benjamin J. Zeskind, in an amount of five million dollars ($5,000,000)
or any other amount satisfactory to the Board of Directors and on terms and conditions satisfactory to the Board of Directors, and will
use commercially reasonable efforts to cause such insurance policies to be maintained until such time as the Board of Directors determines
that such insurance should be discontinued. The key-person policy shall name the Company as loss payee, and neither policy shall
be cancelable by the Company without prior approval by the Board of Directors, including all of the Preferred Directors.

 

    21 

     

    

 

5.2       
 Employee Agreements. The Company will cause (i) each Person
now or hereafter employed by it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent
contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and proprietary rights assignment
agreement; and (ii) each Key Employee to enter into a one (1) year noncompetition and nonsolicitation agreement, substantially in the
form approved by the Board of Directors. The Company has delivered to the Investors copies of all existing agreements between current
employees and consultants, and the Investors agree that these agreements satisfy the requirements of this Section 5.2. In addition,
the Company shall not amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of the above-referenced agreements
or any restricted stock agreement between the Company and any employee, without the approval of the Board of Directors, including all
of the Preferred Directors.

 

5.3        
Employee Stock. Unless otherwise approved by the Board of Directors, including
all of the Preferred Directors, all future employees and consultants of the Company who purchase, receive options to purchase,
or receive awards of shares of the Company’s capital stock after the date hereof shall be required to execute restricted stock
or option agreements, as applicable, providing for (i) vesting of shares over a four (4) year period, with the first twenty-five percent
(25%) of such shares vesting following twelve (12) months of continued employment or service, and the remaining shares vesting in equal
monthly installments over the following thirty-six (36) months, and (ii) a market
stand-off provision substantially similar to that in Subsection
2.11.

 

5.4       
Matters Requiring Investor Director Approval. So long as the holders of Series B Preferred Stock are entitled to elect
a Preferred Director, the Company hereby covenants and agrees with each of the Investors that it shall not, without approval of the Board
of Directors, which approval must include the affirmative vote of all of the Preferred Directors:

 

(a)        
Effect or consummate a public offering of any Capital Stock of the company or any of its subsidiaries, or engage any investment
banking firm or underwriter in connection therewith;

 

(b)        
make, or permit any subsidiary to make, any loan or advance to, or own any stock or other securities of, any subsidiary or other
corporation, partnership, or other entity unless it is wholly owned by the Company;

 

(c)        
make, or permit any subsidiary to make, any loan or advance to any Person, including, without limitation, any employee or director
of the Company or any subsidiary, except advances and similar expenditures in the ordinary course of business or under the terms of an
employee stock or option plan approved by the Board of Directors;

 

(d)       
guarantee, directly or indirectly, or permit any subsidiary to guarantee, directly or indirectly, any indebtedness except for
trade accounts of the Company or any subsidiary arising in the ordinary course of business;

 

(e)        
make any investment inconsistent with any investment policy approved by the Board of Directors;

 

    22 

     

    

 

(f)         
 incur any aggregate indebtedness in excess of $250,000 that is not already included in a budget approved by the Board of Directors,
other than trade credit incurred in the ordinary course of business;

 

(g)        
make any capital expenditures (including expenditures under capitalized leases) that in the aggregate are more than 10% in excess
of the annual budget approved by the Board;;

 

(h)       
otherwise enter into or be a party to any transaction with any director, officer, or employee of the Company or any “associate”
(as defined in Rule 12b-2 promulgated under the Exchange Act) of any such Person, except transactions made in the ordinary course of
business, pursuant to reasonable requirements of the Company’s business and upon fair and reasonable terms that are approved by
the Board of Directors;

 

(i)          
hire, terminate, or change the compensation of the executive officers, including approving any option grants or stock awards to
executive officers;

 

(j)          
change the principal business of the Company, enter unrelated lines of business, or exit the current line of business;

 

(k)        
sell, assign, license, pledge, or encumber material technology or intellectual property, other than the sale of products, services
or licenses granted in the ordinary course of business;

 

(l)         
enter into any corporate strategic relationship involving the payment, contribution, or assignment by the Company or to the Company
of money or assets greater than $200,000, other than agreements for the provision of the Company’s services entered into in the
ordinary course of business;

 

(m)        
increase or decrease the size of the Board of Directors;

 

(n)        
increase or decrease the amount of the Directors and Officers liability insurance;

 

(o)        
amend, modify, terminate, waive, or otherwise alter, in whole or in part, the election procedure of the Board of Directors;

 

(p)        
adopt any plan, or any amendment of any plan, for issuance of any capital stock to employees, directors and consultants; or

 

(q)        
approve the Budget or adopt any material changes or increases cumulatively greater than 15%.

 

5.5        
Board Matters. Unless otherwise determined by the vote of a majority of the directors then in office, the Board of Directors
shall meet at least quarterly in accordance with an agreed-upon schedule. Each Preferred Director shall be entitled in such person’s
discretion to be a member of any committee of the Board of Directors.

 

    23 

     

    

 

5.6        
Successor Indemnification. If the Company or any of its successors or assignees consolidates with or merges into any other
Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper
provisions shall be made so that the successors and assignees of the Company assume the obligations of the Company with respect to indemnification
of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the
Company’s Bylaws, the Certificate of Incorporation, or elsewhere, as the case may be.

 

5.7        
Indemnification Matters. The Company hereby acknowledges that one (1) or more of the Preferred Directors nominated to serve
on the Board of Directors by one (1) or more Investors may have certain rights to indemnification, advancement of expenses and/or insurance
provided by one (1) or more of the Investors and certain of their Affiliates (collectively, the “Investor Indemnitors”).
The Company hereby agrees (a) that it is the indemnitor of first resort (i.e., its obligations to any such Preferred Director
are primary and any obligation of the Investor Indemnitors to advance expenses or to provide indemnification for the same expenses or
liabilities incurred by such Preferred Director are secondary), (b) that it shall be required to advance the full amount of expenses
incurred by such Preferred Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts
paid in settlement by or on behalf of any such Preferred Director to the extent legally permitted and as required by the Certificate
of Incorporation or Bylaws of the Company (or any agreement between the Company and such Preferred Director), without regard to any rights
such Preferred Director may have against the Investor Indemnitors, and, (c) that it irrevocably waives, relinquishes and releases the
Investor Indemnitors from any and all claims against the Investor Indemnitors for contribution, subrogation or any other recovery of
any kind in respect thereof. The Company further agrees that no advancement or payment by the Investor Indemnitors on behalf of any such
Preferred Director with respect to any claim for which such Preferred Director has sought indemnification from the Company shall affect
the foregoing and the Investor Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement
or payment to all of the rights of recovery of such Preferred Director against the Company. The Preferred Directors and the Investor
Indemnitors are intended third-party beneficiaries of this Section 5.7 and shall have the right, power and authority to enforce
the provisions of this Section 5.7 as though they were a party to this Agreement.

 

5.8      
 Right to Conduct Activities. The Company hereby agrees and acknowledges that (i) Boxcar or any of its Affiliates, (ii)
Cormorant or any of its Affiliates, (iii) Surveyor or any of its Affiliates, (iv) Rock Springs or any of its Affiliates, (vi) BlackRock
or any of its Affiliates, (v) T. Rowe Price or any of its Affiliates, (vii) LYFE Capital or any of its Affiliates or (viii) Perceptive
or any of its Affiliates (collectively, the “Professional Investment Organizations”) are professional investment organizations,
and as such review the business plans and related proprietary information of many enterprises, some of which may compete directly or
indirectly with the Company’s business (as currently conducted or as currently propose to be conducted).  The Company hereby
agrees that, to the extent permitted under applicable law, the Professional Investment Organizations shall not be liable to the Company
for any claim arising out of, or based upon, (i) the investment by the Professional Investment Organizations in any entity competitive
with the Company, or (ii) actions taken by any partner, officer, employee or other representative of the Professional Investment Organizations
to assist any such competitive company, whether or not such action was taken as a member of the board of directors of such competitive
company or otherwise, and whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall
not relieve (x) any of the Investors from liability associated with the unauthorized disclosure of the Company’s confidential information
obtained pursuant to this Agreement, or (y) any director or officer of the Company from any liability associated with his or her fiduciary
duties to the Company.

 

    24 

     

    

 

 

5.9             
Defense Production Act. To the extent that the Company learns that it engages in the design, fabrication, development,
testing, production or manufacture of critical technologies within the meaning of Section 721 of the Defense Production Act of 1950,
as amended (50 U.S.C. § 4565), and all rules and regulations thereunder, including as codified at 31 C.F.R. Part 800, whether because
of a new categorization of technology by the U.S. government or otherwise, the Company shall promptly provide notice to Surveyor.

 

5.10         
Class B Common Stock. The Company shall not cause any shares of Class B Common Stock to become subject to the periodic
reporting requirements of Section 12(b) or 12(g) of the Exchange Act without the prior written consent of Surveyor.

 

5.11         
Termination of Covenants. The covenants set forth in this Section 5, except for Subsections 5.6 and 5.7,
shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first
becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation
Event, as such term is defined in the Certificate of Incorporation, whichever event occurs first.

 

6.                 
Miscellaneous.

 

6.1                
Successors and Assigns. The rights under this Agreement
may be assigned (but
only with all related obligations) by a Holder to a transferee
of Registrable Securities that (i) is an Affiliate of a Holder;
(ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s
Immediate Family Members; or (iii) after such transfer, holds at least 143,022 shares
of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations)
or, if less, all of the Registrable Securities held by such Holder;
provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice
of the name and address of such transferee and the Registrable Securities with respect to which
such rights are being transferred; and (y) such transferee agrees
in a written instrument delivered to the Company to be
bound by and subject to the terms and
conditions of this Agreement, including the provisions of Subsection
2.11. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee
(1) that is an Affiliate or stockholder of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a trust for
the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the
transferring Holder; provided further that all transferees who would not qualify individually for assignment of rights shall,
as a condition to the applicable transfer, establish a single attorney-in-fact for the purpose of exercising any rights, receiving notices,
or taking any action under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the
respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon
any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities
under or by reason of this Agreement, except as expressly provided herein.

 

    25 

     

    

 

6.2                
Governing Law. This Agreement and any controversy arising out of or relating to this Agreement shall be governed by and
construed in accordance with the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all
other matters shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts, without regard
to conflict of law principles that would result in the application of any law other than the law of the Commonwealth of Massachusetts.

 

6.3                
Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument. Counterparts
may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN
Act of 2000, e.g., www.docusign.com) or other transmission method
and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

6.4                
Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered
in construing or interpreting this Agreement.

 

6.5                
Notices.

 

(a)              
All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively
given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic
mail or facsimile during the recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s
next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid;
or (iv) one (1) business day after the
business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written
verification of receipt. All communications shall be sent to the respective parties at their addresses as set forth on Schedule A
hereto, or to the principal office of the Company and to the attention
of the Chief Executive Officer, in the case of the Company, or to such email address, facsimile number, or address as subsequently
modified by written notice given in accordance with this Subsection 6.5. If notice is given to the Company, a copy shall also
be sent to Latham & Watkins LLP, 200 Clarendon Street, 27th Floor, Boston, MA 02116, Attention: Evan G. Smith, Esq. and if notice
is given to Investors, a copy shall also be given to: (x) Greenberg Traurig, LLP, One International Place Suite 2000, Boston, MA 02110,
Attention Bradley A. Jacobson, Esq., and (y) Wiggin and Dana LLP, One Century Tower, 265 Church Street, New Haven, Connecticut 06510,
Attention Evan S. Kipperman, Esq.

 

    26 

     

    

 

(b)              
 Consent to Electronic Notice. Each Investor and Key Holder consents to the delivery of any stockholder notice pursuant
to the Delaware General Corporation Law (the “DGCL”), as amended or superseded from time to time, by electronic transmission
pursuant to Section 232 of the DGCL (or any successor thereto) at the electronic mail address as on the books of the Company. Each Investor
agrees to promptly notify the Company of any change in such stockholder’s electronic mail address, and that failure to do so shall
not affect the foregoing.

 

6.6                
Amendments and Waivers. Any term of this Agreement may be amended, modified or terminated and the observance of any term
of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the
written consent of the Company and the holders of a majority of the Registrable Securities then outstanding; provided that the
Company may in its sole discretion waive compliance with Subsection 2.12(c)
(and the Company’s failure to object promptly in writing after
notification of a proposed assignment allegedly in violation of Subsection 2.12(c)
shall be deemed to be a waiver); and provided further
that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party.
Notwithstanding the foregoing, (a) this Agreement may not be amended, modified or terminated and the observance of any term hereof (including,
without limitation, Sections 1.6, 1.7 and 5.4) may not be waived with respect to any Investor without the written
consent of such Investor, unless such amendment, modification, termination, or waiver applies to all Investors in the same fashion (it
being agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to apply to
all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless,
by agreement with the Company, purchase securities in such transaction; provided that if the rights of a Major Investor under Section
4.1 with respect to an offering of New Securities are waived without the consent of such Major Investor, and any Major Investor actually
purchases any New Securities in any such offering, then each Major Investor who did not consent to such waiver shall be permitted to
participate in such offering on a pro rata basis (based on the level of participation of the Major Investor purchasing the largest portion
of such Major Investor’s pro rata share) (b) Sections 1.35, 3.3, 5.9, 5.10 and this clause (b) of this
Subsection 6.6 may not be amended, modified, terminated or waived without the written consent of Surveyor; and (c) Subsections
3.1 and 3.2, Section 4 and any other section of this Agreement applicable to the Major Investors (including this clause
(c) of this Subsection 6.6) may not be amended, modified, terminated or waived without the written consent of the holders of a
majority of the Registrable Securities then outstanding and held by the Major Investors. Notwithstanding the foregoing, Schedule A
hereto may be amended by the Company from time to time to add transferees of any Registrable Securities in compliance with the terms
of this Agreement without the consent of the other parties; and Schedule A hereto may also be amended by the Company after the
date of this Agreement without the consent of the other parties to add information regarding any additional Investor who becomes a party
to this Agreement in accordance with Subsection 6.9. The Company shall give prompt notice of any amendment, modification or termination
hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, modification, termination, or waiver.
Any amendment, modification, termination, or waiver effected in accordance with this Subsection 6.6 shall be binding on all parties
hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision
of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term,
condition, or provision.

 

    27 

     

    

 

6.7                
Severability. In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid,
illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this
Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid, legal, and
enforceable to the maximum extent permitted by law.

 

6.8                
Aggregation of Stock. All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together
for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights
as among themselves in any manner they deem appropriate.

 

6.9                
Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares
of the Company’s Preferred Stock after the date hereof, any purchaser of such shares of Preferred Stock may become a party to this
Agreement by executing and delivering an additional counterpart signature page to this Agreement, and thereafter shall be deemed an “Investor”
for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional
Investor, so long as such additional Investor
has agreed in writing to be bound by all of the obligations as an “Investor” hereunder.

 

6.10            
Entire Agreement. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding
and agreement among the parties with respect to the subject matter
hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled.

 

6.11            
Dispute Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts
of Delaware and to the jurisdiction of the United States District Court for the District of Delaware for the purpose of any suit, action
or other proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising
out of or based upon this Agreement except in the state courts of Delaware or the United States District Court for the District of Delaware,
and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding,
any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from
attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action
or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court.

 

    28 

     

    

 

6.12            
WAIVER OF JURY TRIAL. EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR
ARISING OUT OF THIS AGREEMENT OR THE SUBJECT MATTER HEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL
DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS AGREEMENT, INCLUDING, WITHOUT LIMITATION, CONTRACT
CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN
FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER
WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY
WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.

 

6.13            
Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement,
upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching
or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar
breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or
default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party,
shall be cumulative and not alternative.

 

[Remainder of Page Intentionally Left Blank]

 

    29 

     

    

 

IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.

 

	 	IMMUNEERING CORPORATION
	 	 
	 	By:	/s/
    Benjamin J. Zeskind
	 	Name: Benjamin J. Zeskind
	 	Title:  Chief Executive Officer

  

Signature
Page To Amended and Restated Investors’ Rights Agreement

  

     

     

    

 

	 	INVESTOR:
	 	 
	 	Cormorant
    Private Healthcare Fund III, LP
	 	 
	 	By: Cormorant Private Healthcare GP III,
    LLC
	 	 
	 	By:	/s/
    Bihua Chen
	 	Name: Bihua Chen
	 	Title: Managing Member
	 	 
	 	CORMORANT
    GLOBAL HEALTHCARE MASTER FUND, LP
	 	 
	 	By: Cormorant Global Healthcare GP, LLC
	 	 
	 	By:	/s/ Bihua Chen
	 	Name: Bihua Chen
	 	Title: Managing Member
	 	 
	 	CRMA SPV,
    L.P.
	 	 
	 	By: Cormorant Asset Management, LP
	 	 
	 	By:	/s/ Bihua Chen
	 	Name: Bihua Chen
	 	Title: Attorney-in-fact

 

Signature
Page To Amended and Restated Investors’ Rights Agreement

 

     

     

    

 

	 	INVESTORS:
	 	 
	 	BLACKROCK HEALTH SCIENCES TRUST II
	 	 
	 	By: BlackRock Advisors, LLC, its Investment
    Adviser
	 	 
	 	By:	/s/
    Hongying Erin Xie
	 	Name: Hongying
    Erin Xie
	 	Title: Managing Director

 

Signature
Page To Amended and Restated Investors’ Rights Agreement

  

     

     

    

 

	 	INVESTORS:
	 	 
	 	BOXCAR PMJ,
    LLC
	 	 
	 	By:	/s/
    Joseph Kekst
	 	Name: Joseph
    Kekst
	 	Title: Manager

 

Signature
Page To Amended and Restated Investors’ Rights Agreement

  

     

     

    

 

 

	 	PEF
    LLC
	 	 
	 	By:	/s/
    Peter Feinberg
	 	Name:
	 	Title:

 

Signature
Page To Amended and Restated Investors’ Rights Agreement

 

     

     

    

 

	 	PF
    ASSOCIATES L.P.
	 	 
	 	By:	/s/
    Peter Feinberg
	 	Name:
	 	Title:

 

Signature
Page To Amended and Restated Investors’ Rights Agreement

 

 

     

     

    

 

	 	S4K
    INVESTMENTS LLC
	 	 
	 	By:	/s/
    Peter Feinberg
	 	Name:
	 	Title:

 

Signature
Page To Amended and Restated Investors’ Rights Agreement

 

     

     

    

 

	 	INVESTORS:
	 	 
	 	SAGE
    CREST LLC
	 	 
	 	By:	/s/
    Joseph Kekst
	 	Name:
    Joseph Kekst
	 	Title:
    Manager

 

	 	TSKEK
    IM LLC
	 	 
	 	By:	/s/
    Joseph Kekst
	 	Name:
    Joseph Kekst
	 	Title:
    Manager

 

Signature
Page To Amended and Restated Investors’ Rights Agreement

 

     

     

    

 

	 	ZBC
    CAPITAL PARTNERS LLC
	 	 
	 	By:	/s/
    Marc Hurwitz
	 	Name:
    Marc Hurwitz
	 	Title:
    President

 

Signature
Page To Amended and Restated Investors’ Rights Agreement

 

     

     

    

 

	 	INVESTOR:
	 	 
	 	VALUEQUEST
    PARTNERS, LLC
	 	 
	 	By:	        
	 	Name:
    	 
	 	Title:	                    

 

Signature
Page To Amended and Restated Investors’ Rights Agreement

 

     

     

    

 

	 	INVESTOR:
	 	 
	 	/s/
    Robert J. Carpenter
	 	Robert
    J. Carpenter

 

Signature
Page To Amended and Restated Investors’ Rights Agreement

 

     

     

    

 

	 	INVESTOR:
	 	 
	 	/s/
    Benjamin J. Zeskind
	 	Benjamin
    J. Zeskind

 

Signature
Page To Amended and Restated Investors’ Rights Agreement

 

     

     

    

 

 

	 	INVESTOR:
	 	 
	 	MERRIN INVESTORS
    LLC
	 	 
	 	By:	/s/
    Seth Merrin
	 	Name: Seth
    Merrin
	 	Title: General Partner

 

Signature
Page To Amended and Restated Investors’ Rights Agreement

 

     

     

    

 

	 	INVESTOR:
	 	 
	 	/s/ Martin Lipton
	 	Martin Lipton

 

Signature
Page To Amended and Restated Investors’ Rights Agreement

 

     

     

    

 

	 	INVESTOR:
	 	 
	 	/s/ Harold Levy
	 	Harold Levy

 

Signature
page to amended and restated investors’ rights agreement

 

     

     

    

 

	 	INVESTOR:
	 	 
	 	/s/ Brett M.
    Hall
	 	Brett M. Hall

 

Signature
page to amended and restated investors’ rights agreement

 

     

     

    

 

	 	INVESTOR:
	 	 
	 	/s/ Howard Kaufman
	 	Howard Kaufman

 

Signature
page to amended and restated investors’ rights agreement

 

     

     

    

 

	 	INVESTOR:
	 	 
	 	/s/ Joseph Shenker
	 	Joseph Shenker

 

Signature
page to amended and restated investors’ rights agreement

 

     

     

    

 

	 	INVESTOR:
	 	 
	 	ELI PINEWSKI
    FAMILY LLC
	 	 
	 	By:	/s/
    Alan Pines
	 	Name: Alan
    Pines
	 	Title: Member

 

Signature
page to amended and restated investors’ rights agreement

 

     

     

    

 

	 	INVESTOR:
	 	 
	 	/s/ Kenneth Gruber
	 	Kenneth Gruber

 

Signature
page to amended and restated investors’ rights agreement

 

     

     

    

 

	 	INVESTOR:
	 	 
	 	CITADEL MULTI-STRATEGY EQUITIES MASTER
    FUND LTD.
	 	 
	 	By: Citadel Advisors LLC, its portfolio
    manager
	 	 
	 	By:	/s/
    Shellane Mulcahy
	 	Name:
	 	Title: Authorized Signatory

 

Signature
page to amended and restated investors’ rights agreement

 

     

     

    

 

    

	 	INVESTOR:
	 	 
	 	ROCK SPRINGS CAPITAL MASTER FUND
    LP
	 	 
	 	By: Rock Springs General Partner LLC,
    its general partner
	 	 
	 	By:  	/s/
    Kris Jenner
	 	Name: Kris Jenner
	 	Title: Member
	 	 
	 	FOUR PINES MASTER FUND LP
	 	 
	 	By: Four Pines General Partner LLC,
    its general partner
	 	 
	 	By:  	/s/ Kris Jenner
	 	Name: Kris Jenner
	 	Title: Member

  

Signature
Page To Amended and Restated Investors’ Rights Agreement

  

     

     

    

  

	 	INVESTOR:
	 	 
	 	T. ROWE PRICE HEALTH SCIENCES
    FUND, INC.
	 	TD MUTUAL FUNDS - TD HEALTH SCIENCES
    FUND
	 	T. ROWE PRICE HEALTH SCIENCES
    PORTFOLIO
	 	Each account, severally and not jointly
	 	 
	 	By: T. Rowe Price Associates, Inc.,
    Investment Adviser or Subadviser, as applicable
	 	 
	 	 
	 	By:  	/s/
    Andrew Baek
	 	Name: Andrew Baek
	 	Title: Vice President

  

Signature
Page To Amended and Restated Investors’ Rights Agreement

  

     

     

    

  

	 	INVESTOR:
	 	 
	 	LYFE CAPITAL FUND III (PHOENIX),
    L.P.
	 	 
	 	By:  	/s/
    Yao Li Ho
	 	Name: Yao Li Ho
	 	Title: Member of the General Partner

  

Signature
Page To Amended and Restated Investors’ Rights Agreement

 

     

     

    

  

	 	INVESTOR:
	 	 
	 	PERCEPTIVE LIFE SCIENCES MASTER
    FUND, LTD.
	 	 
	 	By:  	/s/
    James H. Mannix
	 	Name: James H. Mannix
	 	Title: Chief Operating Officer

   

Signature
Page To Amended and Restated Investors’ Rights Agreement

 

     

     

    

  

	 	INVESTOR:
	 	 
	 	BM LINDSEY, INC.
	 	 
	 	By:  	/s/
    Bryan Murphy
	 	Name: Bryan Murphy
	 	Title: Director

  

Signature
Page To Amended and Restated Investors’ Rights Agreement

 

     

     

    

  

	 	INVESTOR:
	 	 
	 	FEINBERG INVESTMENT TRUST LLC
	 	 
	 	By:  	/s/
    Lori Kany
	 	Name:
	 	Title:

  

Signature
Page To Amended and Restated Investors’ Rights Agreement

 

     

     

    

  

	 	INVESTOR:
	 	 
	 	BRIDGELINKS LLC
	 	 
	 	By:  	/s/
    Peter Langerman
	 	Name: Peter Langerman
	 	Title: President

 

Signature
Page To Amended and Restated Investors’ Rights Agreement

 

     

     

    

 

  

	 	INVESTOR:
	 	 
	 	/s/ Rebecca Kusko
	 	Rebecca Kusko

  

Signature
Page To Amended and Restated Investors’ Rights Agreement

 

    

     

    

 

	 	INVESTOR:
	 	 
	 	/s/ Dana Levy
	 	Dana Levy

 

Signature
Page To Amended and Restated Investors’ Rights Agreement

 

    

     

    

  

	 	INVESTOR:
	 	 
	 	/s/ Jonathan Levy
	 	Jonathan Levy

 

Signature
Page To Amended and Restated Investors’ Rights Agreement

  

    

     

    

 

	 	INVESTOR:
	 	 
	 	/s/ Jenna Levy
	 	Jenna Levy

 

Signature
Page To Amended and Restated Investors’ Rights Agreement

 

    

     

    

 

	 	INVESTOR:
	 	 
	 	/s/ Ilonna Rimm
	 	Ilonna Rimm

 

Signature
Page To Amended and Restated Investors’ Rights Agreement

 

    

     

    

 

	 	INVESTOR:
	 	 
	 	/s/ Josef von Rickenbach
	 	Josef von Rickenbach

 

Signature
Page To Amended and Restated Investors’ Rights Agreement

 

    

     

    

 

	 	INVESTOR:
	 	 
	 	/s/ Benjamin Kany
	 	Benjamin Kany

 

Signature
Page To Amended and Restated Investors’ Rights Agreement

 

    

     

    

 

	 	INVESTOR:
	 	 
	 	/s/ Samantha Kany
	 	Samantha Kany

 

Signature
Page To Amended and Restated Investors’ Rights Agreement

 

    

     

    

 

	 	INVESTOR:
	 	 
	 	/s/ Mark Zucker
	 	Mark Zucker

 

Signature
Page To Amended and Restated Investors’ Rights Agreement

 

    

     

    

  

	 	INVESTOR:
	 	 
	 	/s/ Peter King
	 	Peter King

 

Signature
Page To Amended and Restated Investors’ Rights Agreement

 

    

     

    

 

 

	 	INVESTOR:
	 	 
	 	/s/ Scott Barrett
	 	Scott Barrett

 

Signature
Page To Amended and Restated Investors’ Rights Agreement

 

     

     

    

 

	 	INVESTOR:
	 	 
	 	Investor Name:
	 	 
	 	
	 	By:	 
	 	 
	 	Signatory Name (if signing for an entity):
	 	 
	 	 
	 	Title (if signing for an entity):
	 	 

 

Signature
Page To Amended and Restated Investors’ Rights Agreement

 

     

     

    

 

SCHEDULE A

Investors

 

	

    Name and Address of Investor
	Cormorant Private Healthcare Fund III, LP

    [Address]

     

	Cormorant Global Healthcare Master Fund, LP

    [Address]

     

	CRMA SPV, LP

    [Address]

     

	Robert
                                            J. Carpenter
 [Address]

                                                                                 

	Martin
                                            Lipton
 [Address]

                                                                                 

	Josef
                                            von Rickenbach
 [Address]

                                                                                 

	BM
    Lindsey, Inc.

    [Address]

 

     

     

    

 

	PEF
                                            LLC
 [Address]\

                                                                                 

	Tskek
                                            IM LLC
 [Address]

                                                                                 

	Marc
                                            A Hurwitz 2012 Dynasty Trust
 [Address]

                                                                                 

	Feinberg
                                            Investment Trust LLC
 [Address]

                                                                                 

	PF
                                            Associates L.P.
 [Address]

                                                                                 

	S4K
                                            Investments LLC
 [Address]

                                                                                 

	SAGE Crest LLC

    [Address]

     

	ZBC
                                            Capital Partners LLC
 [Address]

                                                                                 

	Benjamin
    J. Zeskind

    [Address]

    

 

     

     

    

 

	Robert
                                            J. Carpenter
 [Address]

                                                                                 

	Rebecca
                                            Kusko
 [Address]

                                                                                 

	Brett
                                            M. Hall
 [Address]

                                                                                 

	Merrin
                                            Investors LLC
 [Address]

                                                                                 

	ValueQuest
                                            Partners, LLC
 [Address]

                                                                                 

	Ken
                                            Gruber
 [Address]

                                                                                 

	Dr.
                                            Mark Zucker
 [Address]

                                                                                 

	Eli
    Pinewski Family LLC

    [Address]

 

     

     

    

 

	Brent
                                            LLC
 [Address]

                                                                                 

	William
                                            Sahlman
 [Address]

                                                                                 

	Bridgelinks
                                            LLC
 [Address]

                                                                                 

	Harold
                                            Levy
 [Address]

                                                                                 

	Dana Levy

    [Address]

     

	Jonathan Levy

    [Address]

     

	Jenna Levy

    [Address]

     

	Haya
    Taitel

    [Address]

 

     

     

    

 

	Mike
                                            Hornbuckle
 [Address]

                                                                                 

	Jon
                                            Mann
 [Address]

                                                                                 

	PENSCO
                                            IRA account Eric Bodner
 [Address]

                                                                                 

	Josh
                                            & Aliza Katz
 [Address]

                                                                                 

	Linda
                                            Jesselson
 [Address]

                                                                                 

	Bruce
                                            A. Bauman and Denise D. Selden, Tenants in Common
 [Address]

                                                                                 

	CARRAL
                                            LLC
 [Address]

                                                                                 

	Premier
    Trust Custodian FBO David Koster IRA

    [Address]

 

     

     

    

 

	Julio
                                            Triana
 [Address]

                                                                                 

	Rochelle
                                            Gut
 [Address]

                                                                                 

	Tyseth
                                            Holdings LLC
 [Address]

                                                                                 

	Blue River Associates, L.P.

    [Address]

     

	Eric F. Saltzman Revocable Trust

    [Address]

     

	Daniel
                                            Giachin
 [Address]

                                                                                 

	Boxcar
    PMJ, LLC

    [Address]
	Adross
    Insights, LLC

    [Address]

 

     

     

    

 

 

	ST
                                            Detroit Enterprises LLC
 [Address]

                                                                                 

	Elisa
                                            and Yoel Wagner
 [Address]

                                                                                 

	The
                                            Livio Giachin Family Trust
 [Address]

                                                                                 

	Business
                                            Technology Advisors, LLC
 [Address]

                                                                                 

	Benjamin Kany

    [Address]

     

	Samantha Kany

    [Address]

     

	Robert and Susan Okin

    [Address]

     

	IRA Services Trust Company

    [Address]

     

 

     

     

    

 

	The Kekst Family Living Trust u/a/d (David J.
    Kekst)

    [Address]

     

	Scott Barrett

    [Address]

     

	Peter King

    [Address]

     

	Ilana’s Trust UT Gershon Kekst Annuity
    Trust

    [Address]

     

	Ronald G. Weiner

    [Address]

     

	55 Pine Street LLC

    [Address]

     

	Kenneth Mandelbaum

    [Address]

     

	ParkEcho Genetica LLC

    [Address]

     

	Louis Feinberg

    [Address]

     

 

     

     

    

 

	Joseph C. Shenker

    [Address]

     

	Raizi Simons

    [Address]

     

	Hali Simons

    [Address]

     

	Zelda Gruber Family Trust

    [Address]

     

	Pam Genet and Elliot Barsh

    [Address]

     

	Ira Rosenberg

    [Address]

     

	Jeremy Triana

    [Address]

     

	Howard Kaufman

    [Address]

     

	Marc A Hurwitz 2012 Dynasty Trust

    [Address]

     

 

     

     

    

 

	T. Rowe Price Health Sciences Fund, Inc.

    [Address]

     

	TD Mutual Funds - TD Health Sciences Fund

    [Address]

     

	T. Rowe Price Health Sciences Portfolio

    [Address]

     

	Citadel Multi-Strategy Equities Master Fund
    Ltd.

    [Address]

    

	Rock Springs Capital Master Fund LP

    [Address]

     

 

     

     

    

 

	Four Pines Master Fund LP

    [Address]

     

	Blackrock Health Sciences Trust II

    [Address]

     

	LYFE Capital Fund III (Phoenix), L.P.

    [Address]

     

	Perceptive Life Sciences Master Fund, Ltd.

    [Address]

     

	Ilonna Rimm

    [Address]

     

 

     

     

    

 

Immuneering
Corporation

 

Amendment
No. 1

to

Amended
and Restated Investors’ Rights Agreement

 

This Amendment No. 1
to Amended and Restated Investors’ Rights Agreement (this “Amendment”), is made and entered into as of
July 23, 2021, by and among Immuneering Corporation (the “Company”) and the Investors signatory hereto.

 

WHEREAS,
the Company, the Investors signatory hereto and other Investors entered into that certain Amended and Restated Investors’ Rights
Agreement, dated as of December 21, 2020 (the “Agreement”);

 

WHEREAS,
pursuant to Section 6.6 of the Agreement, the Agreement may be amended by written agreement of the Company and the Holders of a majority
of the Registrable Securities;

 

WHEREAS,
the Company and the Investors signatory hereto constitute the Holders of a majority of the Registrable Securities; and

 

WHEREAS,
the parties hereto desire to amend the Agreement as set forth herein.

 

NOW,
THEREFORE, for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto
hereby covenant and agree to be bound as follows:

 

1.            Capitalized
Terms. Capitalized terms used herein and not otherwise defined herein shall have the respective meanings assigned to them in the Agreement.

 

2.            Amendments.

 

(a)            Section 1.8
of the Agreement is hereby amended and restated in its entirety to read as follows:

 

“1.12         “Excluded
Registration” means (i) a registration relating to the sale or grant of securities to employees of the Company or a subsidiary
pursuant to a stock option, stock purchase, equity incentive or similar plan; (ii) a registration relating to an SEC Rule 145
transaction; (iii) a registration on any form that does not include substantially the same information as would be required to be
included in a registration statement covering the sale of the Registrable Securities; (iv) a registration in which the only Common
Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered; or (v) a registration
relating to the IPO.”

 

     

     

    

 

(b)            Effective
upon the consummation of the IPO, Section 1.29 of the Agreement is hereby amended and restated in its entirety to read as follows:

 

“1.29.       “Registrable
Securities” means (i) the Common Stock issuable or issued upon conversion of the Preferred Stock; (ii) any Common
Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the
Company, acquired by the Investors prior to the IPO; and (iii) any Common Stock issued as (or issuable upon the conversion or exercise
of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in
replacement of, the shares referenced in clauses (i) and (ii) above; excluding in all cases, however, any Registrable
Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to Subsection 6.1,
and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Subsection
2.13 of this Agreement.”

 

(c)            Section 6.5
of the Agreement is hereby amended and restated in its entirety to read as follows:

 

“Section 6.5. Notices.

 

(a)            All
notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon
the earlier of actual receipt or: (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail
or facsimile during the recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s
next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage
prepaid; or (iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight
prepaid, specifying next-day delivery, with written verification of receipt. All communications shall be sent to the respective parties
at their addresses as set forth on Schedule A hereto or as on the books and records of the Company, or to the principal office
of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to such electronic mail address, facsimile
number, or address as subsequently modified by written notice given in accordance with this Subsection 6.5. If notice is given
to the Company, a copy shall also be sent to Latham & Watkins LLP, 200 Clarendon Street, 27th Floor, Boston, MA 02116, Attention:
Evan G. Smith, Esq. and if notice is given to Investors, a copy shall also be given to: (x) Greenberg Traurig, LLP, One International
Place Suite 2000, Boston, MA 02110, Attention Bradley A. Jacobson, Esq., and (y) Wiggin and Dana LLP, One Century Tower,
265 Church Street, New Haven, Connecticut 06510, Attention Evan S. Kipperman, Esq.

 

(b)            Each
Investor consents to the delivery of any stockholder notice pursuant to the General Corporation Law of the State of Delaware (the “DGCL”),
as amended or superseded from time to time, by electronic transmission pursuant to Section 232 of the DGCL (or any successor thereto)
at the electronic mail address or the facsimile number set forth below such Investor’s name on Schedule A hereto, as updated
from time to time by notice to the Company, or as on the books and records of the Company. Each Investor agrees to promptly notify the
Company of any change in such stockholder’s electronic mail address, and that failure to do so shall not affect the foregoing.”

 

    2 

     

    

 

(d)            Effective
upon the consummation of the IPO, Section 6.6 of the Agreement is hereby amended and restated in its entirety to read as follows:

 

“6.6. Amendments and Waivers. Any term of this
Agreement may be amended, modified or terminated and the observance of any term of this Agreement may be waived (either generally or in
a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of a majority
of the Registrable Securities then outstanding; provided that the Company may in its sole discretion waive compliance with Subsection
2.12(c) (and the Company’s failure to object promptly in writing after notification of a proposed assignment allegedly
in violation of Subsection 2.12(c) shall be deemed to be a waiver); and provided further that any provision hereof
may be waived by any waiving party on such party’s own behalf, without the consent of any other party. Notwithstanding the foregoing,
(a) this Agreement may not be amended, modified or terminated and the observance of any term hereof (including, without limitation,
Sections 1.6, 1.7 and 5.4) may not be waived with respect to any Investor without the written consent of such Investor,
unless such amendment, modification, termination, or waiver applies to all Investors in the same fashion and (b) Schedule A
hereto may be amended by the Company from time to time to add transferees of any Registrable Securities in compliance with the terms of
this Agreement without the consent of the other parties. Any amendment, modification, termination, or waiver effected in accordance with
this Subsection 6.6 shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No
waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or
construed as a further or continuing waiver of any such term, condition, or provision.”

 

3.            Effective
Date. This Amendment shall be effective upon the execution hereof by the Company and the Holders of a majority of the Registrable
Securities.

 

4.            No
Further Amendment. Except as expressly amended hereby, the Agreement is in all respects ratified and confirmed and all of the terms
and conditions and provisions thereof shall remain in full force and effect. This Amendment is limited precisely as written and, except
as set forth in Section 2 of this Amendment, shall not be deemed to be an amendment to any other term or condition of the Agreement
or any of the documents referred to therein. In the event of a conflict between the terms of the Agreement and the terms of this Amendment,
the terms of this Amendment shall control.

 

5.            Effect
of Amendment. This Amendment shall form a part of the Agreement for all purposes, and each party thereto and hereto shall be bound
hereby. From and after the execution of this Amendment by the parties hereto, any reference in the Agreement to “this Agreement,”
 “hereof,” “herein,” “hereunder” and words or expressions of similar import shall be deemed a reference
to the Agreement as amended hereby. Upon execution of this Amendment by the Company and the Holders of a majority of the Registrable
Securities, this Amendment shall be binding on all parties to the Agreement, regardless of whether such party has consented to this Amendment.

 

    3 

     

    

 

6.            Governing
Law. This Amendment and any controversy arising out of or relating to this Amendment shall be governed by and construed in accordance
with the internal laws of the State of Delaware, without regard to conflict of law principles that would result in the application of
any law other than the law of the State of Delaware.

 

7.            Captions.
All articles and section headings or captions contained in this Amendment are inserted only as a matter of convenience and for reference
and in no way define, limit, extend or describe the scope of this Amendment or the intent of any provision thereof.

 

8.            Severability.
If any provision of this Amendment or application to any party or circumstance shall be determined by any court of competent jurisdiction
to be invalid or unenforceable to any extent, the remainder of this Amendment or the application of such provision to any other party
or circumstances shall not be affected thereby, and each provision shall be valid and shall be enforced to the fullest extent permitted
by law.

 

9.            Counterparts;
Execution. This Amendment may be executed in counterparts, each of which so executed shall be deemed to be an original, and all of
which together shall constitute one instrument. Delivery or acceptance of this Amendment or any portion thereof by facsimile transmission
or digitally, or in any electronic fashion or other transmission method (including without limitation, pdf or any electronic signature
complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com), shall have the same effect as if delivered personally and
any such transmission signature, initial or notation, shall have the same effect as if it were an original and shall be binding upon the
maker thereof.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

    4 

     

    

 

IN
WITNESS WHEREOF, each of the undersigned has executed this Amendment No. 1 to Amended and Restated Investors’ Rights
Agreement as of the date first written above.

 

	 	COMPANY:
	 	 
	 	IMMUNEERING CORPORATION

 

		By:	/s/
Benjamin J. Zeskind

		Name:	Benjamin
J. Zeskind, Ph.D.
	 	Title:	Chief Executive Officer

 

[Signature Page to Amendment No. 1
to Amended and Restated Investors’ Rights Agreement]

     

     

    

 

IN
WITNESS WHEREOF, each of the undersigned has executed this Amendment No. 1 to Amended and Restated Investors’ Rights
Agreement as of the date first written above.

 

	 	INVESTOR:
	 	 
	 	 
	 	Cormorant Private
                                            Healthcare Fund III, LP
	 	 
	 	By: Cormorant Private Healthcare GP III, LLC
	 	 

 

		By:	/s/
Bihua Chen

		Name:	 Bihua Chen

		Title:	 Managing Member

 

 

	 	CORMORANT GLOBAL
HEALTHCARE MASTER FUND, LP

 

	 	By: Cormorant Global Healthcare GP, LLC

 

 

		By:	/s/
Bihua Chen

		Name:	 Bihua Chen

		Title:	 Managing Member

 

 

	 	CRMA
                                            SPV, L.P.

 

	 	By: Cormorant Asset Management, LP

 

 

		By:	/s/
Bihua Chen

		Name:	 Bihua Chen

		Title:	  Attorney-in-fact

 

[Signature Page to Amendment No. 1
to Amended and Restated Investors’ Rights Agreement]

 

     

     

    

 

IN
WITNESS WHEREOF, each of the undersigned has executed this Amendment No. 1 to Amended and Restated Investors’ Rights
Agreement as of the date first written above.

 

	 	INVESTORS:
	 	 
	 	 
	 	BLACKROCK HEALTH SCIENCES TRUST II
	 	 
	 	By: BlackRock Advisors, LLC, its Investment Adviser
	 	 

 

		By:	/s/
Hongying Erin Xie

		Name:	  Hongying Erin Xie

		Title:	  Managing Director

 

[Signature Page to Amendment No. 1
to Amended and Restated Investors’ Rights Agreement]

 

     

     

    

 

IN
WITNESS WHEREOF, each of the undersigned has executed this Amendment No. 1 to Amended and Restated Investors’ Rights
Agreement as of the date first written above.

 

	 	INVESTORS:
	 	 
	 	 
	 	BOXCAR PMJ, LLC
	 	 

 

		By:	/s/
Joseph Kekst

		Name:	   Joseph Kekst

		Title:	  Manager

 

[Signature Page to Amendment No. 1
to Amended and Restated Investors’ Rights Agreement]

 

     

     

    

 

	 	INVESTORS:
	 	 
	 	 
	 	PEF LLC

 

		By:	/s/ Peter Feinberg

		Name:	    Peter Feinberg

		Title:	  Partner

 

[Signature Page to Amendment No. 1
to Amended and Restated Investors’ Rights Agreement]

 

     

     

    

 

IN
WITNESS WHEREOF, each of the undersigned has executed this Amendment No. 1 to Amended and Restated Investors’ Rights
Agreement as of the date first written above.

 

	 	INVESTORS:
	 	 
	 	 
	 	PF ASSOCIATES L.P.

 

		By:	/s/
Peter Feinberg

		Name:	    

		Title:	  

 

 

[Signature Page to Amendment No. 1
to Amended and Restated Investors’ Rights Agreement]

 

     

     

    

 

IN
WITNESS WHEREOF, each of the undersigned has executed this Amendment No. 1 to Amended and Restated Investors’ Rights
Agreement as of the date first written above.

 

	 	INVESTORS:
	 	 
	 	 
	 	S4K INVESTMENTS LLC

 

		By:	/s/
Peter Feinberg

		Name:	    

		Title:	  

 

[Signature Page to Amendment No. 1
to Amended and Restated Investors’ Rights Agreement]

 

     

     

    

 

IN
WITNESS WHEREOF, each of the undersigned has executed this Amendment No. 1 to Amended and Restated Investors’ Rights
Agreement as of the date first written above.

 

	 	INVESTORS:
	 	 
	 	 
	 	SAGE CREST LLC

 

		By:	/s/ Joseph Kekst

		Name:	     Joseph Kekst

		Title:	  Manager

 

 

	 	TSKEK IM LLC

 

		By:	/s/ Joseph Kekst

		Name:	     Joseph Kekst

		Title:	  Manager

 

[Signature Page to Amendment
No. 1 to Amended and Restated Investors’ Rights Agreement]

 

     

     

    

 

 

IN
WITNESS WHEREOF, each of the undersigned has executed this Amendment No. 1 to Amended and Restated Investors’ Rights
Agreement as of the date first written above.

 

	 	INVESTOR:
	 	 
	 	ZBC CAPITAL PARTNERS LLC
	 	 
	 	By:	/s/ Marc Hurwitz
	 	Name: Marc Hurwitz
	 	Title: President

 

[Signature Page to
Amendment No. 1 to Amended and Restated Investors’ Rights Agreement]

 

     

     

    

 

IN
WITNESS WHEREOF, each of the undersigned has executed this Amendment No. 1 to Amended and Restated Investors’ Rights
Agreement as of the date first written above.

 

	 	INVESTOR:
	 	 
	 	/s/ Robert J. Carpenter
	 	Robert J. Carpenter

 

[Signature Page to Amendment No. 1
to Amended and Restated Investors’ Rights Agreement]

 

     

     

    

 

IN
WITNESS WHEREOF, each of the undersigned has executed this Amendment No. 1 to Amended and Restated Investors’ Rights
Agreement as of the date first written above.

 

	 	INVESTOR:
	 	 
	 	/s/ Benjamin J. Zeskind
	 	Benjamin J. Zeskind

 

[Signature Page to Amendment No. 1
to Amended and Restated Investors’ Rights Agreement]

 

     

     

    

 

IN
WITNESS WHEREOF, each of the undersigned has executed this Amendment No. 1 to Amended and Restated Investors’ Rights
Agreement as of the date first written above.

 

	 	INVESTOR:
	 	 
	 	MERRIN INVESTORS LLC
	 	 
	 	By:	/s/ Seth Merrin
	 	Name: Seth Merrin
	 	Title: General Partner

 

[Signature Page to Amendment No. 1
to Amended and Restated Investors’ Rights Agreement]

 

     

     

    

 

IN
WITNESS WHEREOF, each of the undersigned has executed this Amendment No. 1 to Amended and Restated Investors’ Rights
Agreement as of the date first written above.

 

	 	INVESTOR:
	 	 
	 	CITADEL MULTI-STRATEGY EQUITIES MASTER FUND LTD.
	 	 
	 	By: Citadel Advisors LLC, its portfolio manager
	 	 
	 	By:	/s/ Shellane Mulcahy
	 	Name:
	 	Title: Authorized Signatory

 

[Signature Page to Amendment No. 1
to Amended and Restated Investors’ Rights Agreement]

 

     

     

    

 

IN
WITNESS WHEREOF, each of the undersigned has executed this Amendment No. 1 to Amended and Restated Investors’ Rights
Agreement as of the date first written above.

 

	 	INVESTOR:
	 	 
	 	ROCK SPRINGS CAPITAL MASTER FUND LP
	 	 
	 	By: Rock Springs General Partner LLC, its general partner
	 	 
	 	By:	/s/ Kris Jenner
	 	Name: Kris Jenner
	 	Title: Member
	 	 
	 	FOUR PINES MASTER FUND LP
	 	 
	 	By: Four Pines General Partner LLC, its general partner
	 	 
	 	By: 	/s/ Kris Jenner
	 	Name: Kris Jenner
	 	Title: Member

 

[Signature Page to Amendment No. 1
to Amended and Restated Investors’ Rights Agreement]

 

     

     

    

 

IN
WITNESS WHEREOF, each of the undersigned has executed this Amendment No. 1 to Amended and Restated Investors’ Rights
Agreement as of the date first written above.

 

	 	INVESTOR:
	 	 
	 	T. ROWE PRICE HEALTH SCIENCES FUND, INC.
	 	TD MUTUAL FUNDS - TD HEALTH SCIENCES FUND
	 	T. ROWE PRICE HEALTH SCIENCES PORTFOLIO
	 	Each account, severally and not jointly
	 	 
	 	By: T. Rowe Price Associates, Inc., Investment Adviser or Subadviser, as applicable
	 	 
	 	By:	/s/ Andrew Baek
	 	Name: Andrew Baek
	 	Title: Vice President

 

[Signature Page to Amendment No. 1
to Amended and Restated Investors’ Rights Agreement]

 

     

     

    

 

IN
WITNESS WHEREOF, each of the undersigned has executed this Amendment No. 1 to Amended and Restated Investors’ Rights
Agreement as of the date first written above.

 

	 	INVESTOR:
	 	 
	 	LYFE CAPITAL FUND III (PHOENIX), L.P.
	 	 
	 	By:	/s/ Yao Li Ho
	 	Name: Yao Li Ho
	 	Title: Member of the General Partner

 

[Signature Page to Amendment No. 1
to Amended and Restated Investors’ Rights Agreement]

 

     

     

    

 

IN
WITNESS WHEREOF, each of the undersigned has executed this Amendment No. 1 to Amended and Restated Investors’ Rights
Agreement as of the date first written above.

 

	 	INVESTOR:
	 	 
	 	PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.
	 	 
	 	By:	/s/ James H. Mannix
	 	Name: James H. Mannix
	 	Title: Chief Operating Officer

 

[Signature Page to Amendment No. 1
to Amended and Restated Investors’ Rights Agreement]

 

     

     

    

 

IN
WITNESS WHEREOF, each of the undersigned has executed this Amendment No. 1 to Amended and Restated Investors’ Rights
Agreement as of the date first written above.

 

	 	INVESTOR:
	 	 
	 	FEINBERG INVESTMENT TRUST LLC
	 	 
	 	By: Lori Feinberg Kany
	 	Its: Trustee
	 	 
	 	By:	/s/ Lori Kany
	 	Name:
	 	Title:

 

[Signature Page to Amendment No. 1
to Amended and Restated Investors’ Rights Agreement]

 

     

     

    

 

IN
WITNESS WHEREOF, each of the undersigned has executed this Amendment No. 1 to Amended and Restated Investors’ Rights
Agreement as of the date first written above.

 

	 	INVESTOR:
	 	 
	 	/s/ Dana Levy
	 	Dana Levy

 

[Signature Page to Amendment No. 1
to Amended and Restated Investors’ Rights Agreement]

 

     

     

    

 

IN
WITNESS WHEREOF, each of the undersigned has executed this Amendment No. 1 to Amended and Restated Investors’ Rights
Agreement as of the date first written above.

 

	 	INVESTOR:
	 	 
	 	/s/ Jonathan H. Levy
	 	Jonathan H. Levy

 

[Signature Page to Amendment No. 1
to Amended and Restated Investors’ Rights Agreement]

 

     

     

    

 

IN
WITNESS WHEREOF, each of the undersigned has executed this Amendment No. 1 to Amended and Restated Investors’ Rights
Agreement as of the date first written above.

 

	 	INVESTOR:
	 	 
	 	/s/ Jenna Levy
	 	Jenna Levy

 

[Signature Page to Amendment No. 1
to Amended and Restated Investors’ Rights Agreement]Exhibit 10.5

 

Employment Agreement

 

This Employment Agreement (this
 “Agreement”), dated as of July 23, 2021, is made by and between Immuneering Corporation, a Delaware corporation
(together with any successor thereto, the “Company”), and Biren Amin (“Executive”)
(collectively referred to herein as the “Parties” or individually referred to as a “Party”),
and will become effective, if at all, upon the date of the Company’s initial public offering of common stock
(“IPO”) pursuant to an effective registration statement filed under the Securities Act of 1933, as amended (the
 “Effective Date”).

 

RECITALS

 

		A.	It is the desire of the Company to assure itself of the services of Executive as
of the Effective Date and thereafter by entering into this Agreement.

 

		B.	Executive and the Company mutually desire that Executive provide services to the Company
on the terms herein provided.

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the
foregoing and of the respective covenants and agreements set forth below, the Parties hereto agree as follows:

 

		1.	Employment.

 

(a)         
General. Effective on the Effective Date, the Company shall employ Executive, and Executive shall be employed by the Company,
for the period and in the positions set forth in this Section 1, and subject to the other terms and conditions herein provided;
provided, however, that this Agreement is expressly conditioned upon the IPO closing before December 31, 2021 and will be null and void
if this condition is not satisfied.

 

(b)          
At-Will Employment. The Company and Executive acknowledge that Executive’s employment is and shall continue to be at-will,
as defined under applicable law, and that Executive’s employment with the Company may be terminated by either Party at any time
for any or no reason (subject to the notice requirements of Section 3(b)). This “at-will” nature of Executive’s
employment shall remain unchanged during Executive’s tenure as an employee and may not be changed, except in an express writing
signed by Executive and a duly authorized officer of the Company. If Executive’s employment terminates for any reason, Executive
shall not be entitled to any payments, benefits or compensation other than as provided in this Agreement or otherwise agreed to in writing
by the Company or as provided by applicable law. The term of this Agreement (the “Term”) shall commence on the

Effective Date and end on the date this Agreement
is terminated under Section 3.

 

(c)           Positions
and Duties. During the Term, Executive shall serve as Chief Financial Officer of the Company, with such responsibilities, duties
and authority normally associated with such position and as may from time to time be assigned to Executive by the Chief Executive
Officer of the Company (the “CEO”). Executive shall devote substantially all of Executive’s working time
and efforts to the business and affairs of the Company (which shall include service to its affiliates, if applicable) and shall not
engage in outside business activities (including serving on outside boards or committees) without the consent of the Board of
Directors of the Company or an authorized committee thereof (in either case, the “Board”), provided that
Executive shall be permitted to (i) manage Executive’s personal, financial and legal affairs, (ii) participate in trade
associations, and (iii) serve on the board of directors of not-for-profit or tax-exempt charitable organizations, in each case,
subject to compliance with this Agreement and provided that such activities do not materially interfere with Executive’s
performance of Executive’s duties and responsibilities hereunder. Executive agrees to observe and comply with the rules and
policies of the Company as adopted by the Company from time to time, in each case, as amended from time to time, and as delivered or
made available to Executive (each, a “Policy”).

 

     

     

    

 

		2.	Compensation and Related Matters.

 

(a)         
Annual Base Salary. During the Term, Executive shall receive a base salary at a rate of $450,000 per annum, which shall
be paid in accordance with the customary payroll practices of the Company and shall be pro-rated for partial years of employment. Such
annual base salary shall be reviewed (and may be adjusted) from time to time by the Board (such annual base salary, as it may be adjusted
from time to time, the “Annual Base Salary”).

 

(b)           Annual
Cash Bonus Opportunity. During the Term, Executive will be eligible to participate in an annual incentive program established by
the Board. Executive’s annual incentive compensation under such incentive program (the “Annual Bonus”)
shall be targeted at 40% of Executive’s Annual Base Salary (such target, as may be adjusted by the Board from time to time,
the “Target Annual Bonus”). The Annual Bonus payable under the incentive program shall be based on the
achievement of performance goals to be determined by the Board and may in the Board’s discretion be calculated in a manner
intended to reflect any mid-year changes in Annual Base Salary or Target Annual Bonus. The payment of any Annual Bonus pursuant to
the incentive program shall be subject to Executive’s continued employment with the Company through the date of payment,
except as otherwise provided in Section 4(b).

 

(c)          
Benefits. During the Term, Executive shall be eligible to participate in employee benefit plans, programs and arrangements
of the Company, subject to the terms and eligibility requirements thereof and as such plans, programs and arrangements may be amended
or in effect from time to time. In no event shall Executive be eligible to participate in any severance plan or program of the Company,
except as set forth in Section 4 of this Agreement.

 

(d)         
Vacation. During the Term, Executive shall be entitled to paid personal leave in accordance with the Company’s Policies.
Any vacation shall be taken at the reasonable and mutual convenience of the Company and Executive.

 

(e)          
Business Expenses. During the Term, the Company shall reimburse Executive for all reasonable travel and other business expenses
incurred by Executive in the performance of Executive’s duties to the Company in accordance with the Company’s expense reimbursement
Policy.

 

(f)           Key Person Insurance. At
any time during the Term, the Company shall have the right (but not the obligation) to insure the life of Executive for the
Company’s sole benefit. The Company shall have the right to determine the amount of insurance and the type of policy.
Executive shall reasonably cooperate with the Company in obtaining such insurance by submitting to physical examinations, by
supplying all information reasonably required by any insurance carrier, and by executing all necessary documents reasonably required
by any insurance carrier, provided that any information provided to an insurance company or broker shall not be provided to the
Company without the prior written authorization of Executive. Executive shall incur no financial obligation by executing any
required document, and shall have no interest in any such policy.

 

    2 

     

    

 

3.       Termination.

 

Executive’s employment hereunder and the Term may
be terminated by the Company or Executive, as applicable, without any breach of this Agreement under the following circumstances and
the Term will end on the Date of Termination:

 

		(a)	Circumstances.

 

		(i)	Death. Executive’s employment hereunder shall terminate upon Executive’s death.

 

		(ii)	Disability. If Executive has incurred a Disability, as defined below, the Company may terminate Executive’s
employment.

 

(iii)         
Termination for Cause. The Company may terminate Executive’s employment for Cause, as defined below.

 

(iv)         
Termination without Cause. The Company may terminate Executive’s employment without Cause.

 

(v)          Resignation
from the Company with Good Reason. Executive may resign Executive’s employment with the Company with Good Reason, as
defined below.

 

(vi)         Resignation
from the Company without Good Reason. Executive may resign Executive’s employment with the Company for any reason other
than Good Reason or for no reason.

 

(b)          
Notice of Termination. Any termination of Executive’s employment by the Company or by Executive under this Section 3
(other than termination pursuant to Section 3(a)(i)) shall be communicated by a written notice to the other Party hereto (i) indicating
the specific termination provision in this Agreement relied upon, (ii) setting forth in reasonable detail the facts and circumstances
claimed to provide a basis for termination of Executive’s employment under the provision so indicated, if applicable, and (iii)
specifying a Date of Termination which, if submitted by Executive, shall be at least thirty (30) days following the date of such notice
(a “Notice of Termination”); provided, however, that in the event that Executive delivers a Notice of Termination
to the Company, the Company may, in its sole discretion, change the Date of Termination to any date that occurs following the date of
the Company’s receipt of such Notice of Termination and is prior to the date specified in such Notice of Termination, but the termination
will still be considered a resignation by Executive. A Notice of Termination submitted by the Company may provide for a Date of Termination
on the date Executive receives the Notice of Termination, or any date thereafter elected by the Company. The failure by either Party to
set forth in the Notice of Termination any fact or circumstance which contributes to a showing of Cause or Good Reason shall not waive
any right of the Party hereunder or preclude the Party from asserting such fact or circumstance in enforcing the Party’s rights
hereunder.

 

(c)           Company
Obligations upon Termination. Upon termination of Executive’s employment pursuant to any of the circumstances listed in
this Section 3, Executive (or Executive’s estate) shall be entitled to receive the sum of: (i) the portion of
Executive’s Annual Base Salary earned through the Date of Termination, but not yet paid to Executive; (ii) any expense
reimbursements owed to Executive pursuant to Section 2(e); and (iii) any amount accrued and arising from Executive’s
participation in, or benefits accrued under any employee benefit plans, programs or arrangements, which amounts shall be payable in
accordance with the terms and conditions of such employee benefit plans, programs or arrangements (collectively, the
 “Company Arrangements”). Except as otherwise expressly required by law (e.g., COBRA) or as specifically
provided herein, all of Executive’s rights to salary, severance, benefits, bonuses and other compensatory amounts hereunder
(if any) shall cease upon the termination of Executive’s employment hereunder.

 

    3 

     

    

 

		(d)	Deemed Resignation. Upon termination of Executive’s employment for any reason, Executive shall be deemed to have resigned
from all offices and directorships, if any, then held with the Company or any of its subsidiaries.

 

		4.	Severance Payments.

 

(a)           Termination
for Cause, or Termination Upon Death, Disability or Resignation from the Company Without Good Reason. If Executive’s
employment shall terminate as a result of Executive’s death pursuant to Section 3(a)(i) or Disability pursuant to Section
3(a)(ii), pursuant to Section 3(a)(iii) for Cause, or pursuant to Section 3(a)(vi) for Executive’s
resignation from the Company without Good Reason, then Executive shall not be entitled to any severance payments or benefits, except
as provided in Section 3(c).

 

(b)           Termination
without Cause, or Resignation from the Company with Good Reason. If Executive’s employment terminates without Cause
pursuant to Section 3(a)(iv), or pursuant to Section 3(a)(v) due to Executive’s resignation with Good Reason,
then except as otherwise provided under Section 4(c) and subject to Executive signing on or before the 21st day following
Executive’s Separation from Service (as defined below), and not revoking, a release of claims substantially in the form
attached as Exhibit A to this Agreement (the “Release”) and Executive’s continued compliance with Section
5, Executive shall receive, in addition to payments and benefits set forth in Section 3(c), the following:

 

		(i)	an amount in cash equal to 1.0 times the Annual Base Salary,
payable in the form of salary continuation in regular installments over the 12 month period following the date of Executive’s Separation from Service
(the “Severance Period”) in accordance with the Company’s normal payroll practices;

 

		(ii)	to the extent unpaid as of the Date of Termination, an amount of cash equal to any Annual Bonus earned by Executive for the Company’s
fiscal year prior to the fiscal year in which the Date of Termination occurs, as determined by the Board in its discretion based upon
actual performance achieved, which Annual Bonus, if any, shall be paid to Executive in the fiscal year in which the Date of Termination
occurs when bonuses for such prior fiscal year are paid in the ordinary course to actively employed senior executives of the Company;
and

 

		(iii)	if Executive timely elects to receive continued medical, dental or vision coverage under one or more
                                                                                 of the Company’s group medical, dental or vision plans pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985,
                                                                                 as amended (“COBRA”), then the Company shall directly pay, or reimburse Executive for, the COBRA premiums for
                                                                                 Executive and Executive’s covered dependents under such plans, less the amount Executive would have had to pay to receive such
                                                                                 coverage as an active employee based on the cost sharing levels in effect on the Date of Termination, during the period commencing
                                                                                 on Executive’s Separation from Service and ending upon the earliest of (A) the last day of the Severance Period, (B) the date
                                                                                 that Executive and/or Executive’s covered dependents become no longer eligible for COBRA and (C) the date Executive becomes
                                                                                 eligible to receive medical, dental or vision coverage, as applicable, from a subsequent employer (and Executive agrees to promptly
notify the Company of such eligibility) (the “COBRA Continuation Period”). Notwithstanding the foregoing, if the Company
determines it cannot provide the foregoing benefit without potentially violating applicable law (including, without limitation, Section
2716 of the Public Health Service Act) or incurring an excise tax, the Company shall in lieu thereof provide to Executive a taxable monthly
payment in an amount equal to the monthly COBRA premium that Executive would be required to pay to continue Executive’s and Executive’s
covered dependents’ group health coverage in effect on the Date of Termination (which amount shall be based on the premium
for the first month of COBRA coverage), less the amount Executive would have had to pay to receive such group health coverage as an active
employee for Executive and his or her covered dependents based on the cost sharing levels in effect on the Date of Termination, which
payments shall be made for the remainder of the COBRA Continuation Period.

 

    4 

     

    

 

(c)          
Change in Control. In lieu of the payments and benefits set forth in Section 4(b), in the event Executive’s
employment terminates without Cause pursuant to Section 3(a)(iv), or pursuant to Section 3(a)(v) due to Executive’s
resignation with Good Reason, in either case, on or within twelve (12) months following the date of a Change in Control, subject to Executive
signing on or before the 21st day following Executive’s Separation from Service, and not revoking, the Release and Executive’s
continued compliance with Section 5, Executive shall receive, in addition to the payments and benefits set forth in Section
3(c), the following:

 

(i)           
an amount in cash equal to 1.0 times the Annual Base Salary, payable in equal installments over the 12 month period following the date
of Executive’s Separation from Service (the “CIC Severance Period”) in accordance with the Company’s normal
payroll practices;

 

		(ii)	the payment set forth in Section 4(b)(ii);

 

		(iii)	the benefits set forth in Section 4(b)(iii), provided that for this purpose, the

 

“Severance Period” will
mean the CIC Severance Period;

 

(iv)         
an amount in cash equal to 1.0 times the Target Annual Bonus, payable in a lump sum on the Company’s first ordinary payroll date
that occurs after the Date of Termination; and

 

(v)          
all unvested equity or equity-based awards held by Executive under any Company equity compensation plans that vest solely based
on continued employment or service shall immediately become 100% vested, with any other equity or equity-based awards being governed by
the terms of the applicable award agreement.

 

(d)          
Survival. Notwithstanding anything to the contrary in this Agreement, the provisions of Sections 5 through 9 will
survive the termination of Executive’s employment and the termination of the Term.

 

5.           
Restrictive Covenants. As a condition to the effectiveness of this Agreement, Executive will have executed and
delivered to the Company no later than contemporaneously herewith the Employee Proprietary Information and Inventions Assignment Agreement
attached as Exhibit B (the “Restrictive Covenant Agreement”). Executive agrees to abide by the terms of the
Restrictive Covenant Agreement, which are hereby incorporated by reference into this Agreement. Executive acknowledges that the provisions
of the Restrictive Covenant Agreement will survive the termination of Executive’s employment and the termination of the Term for
the periods set forth in the Restrictive Covenant Agreement.

 

    5 

     

    

 

6.       Assignment
and Successors.

 

The Company may assign its rights and obligations
under this Agreement to any of its affiliates or to any successor to all or substantially all of the business or the assets of the Company
(by merger or otherwise), and may assign or encumber this Agreement and its rights hereunder as security for indebtedness of the Company
and its affiliates. This Agreement shall be binding upon and inure to the benefit of the Company, Executive and their respective successors,
assigns, personal and legal representatives, executors, administrators, heirs, distributees, devisees, and legatees, as applicable. None
of Executive’s rights or obligations may be assigned or transferred by Executive, other than Executive’s rights to payments
hereunder, which may be transferred only by will or operation of law. Notwithstanding the foregoing, Executive shall be entitled, to the
extent permitted under applicable law and applicable Company Arrangements, to select and change a beneficiary or beneficiaries to receive
compensation hereunder following Executive’s death by giving written notice thereof to the Company.

 

		7.	Certain Definitions.

 

		(a)	Cause. The Company shall have “Cause” to terminate Executive’s employment hereunder upon:

 

 (i)             The Board’s
reasonable, good faith determination that Executive has refused to (A) substantially perform the duties
associated with Executive’s position with the Company or (B) carry out the reasonable and lawful instructions of
the Board concerning duties or actions consistent with the Executive’s position with the Company, in each case, that, to the extent
capable of cure, has remained uncured for a period of thirty (30) days following written notice from the Company;

 

(ii)          
Executive’s breach of a material provision of this Agreement that, to the extent capable of cure, has remained uncured for
a period of thirty (30) days following written notice from the Company;

 

(iii)         
Executive’s conviction, plea of no contest, plea of nolo contendere, or imposition of unadjudicated probation for
any felony or crime involving moral turpitude;

 

(iv)         
Executive’s unlawful use (including being under the influence) or possession of illegal drugs on the Company’s (or
any of its affiliate’s) premises or while performing Executive’s duties and responsibilities under this Agreement; or

 

(v)          
Executive’s commission of any act of fraud, embezzlement, misappropriation, willful misconduct, or breach of fiduciary duty against
the Company or any of its affiliates.

 

 (b)         
 Change in Control. “Change in Control” shall have the meaning set forth in the Immuneering Corporation 2021 Incentive Award Plan, as in effect on the Effective Date.

 

(c)          
Code. “Code” shall mean the Internal Revenue Code of 1986, as amended, and the regulations and guidance promulgated
thereunder.

 

(d)          
Date of Termination. “Date of Termination” shall mean (i) if Executive’s employment is terminated by Executive’s
death, the date of Executive’s death; or (ii) if Executive’s employment is terminated pursuant to Section 3(a)(ii)
 – (vi) either the date indicated in the Notice of Termination or the date specified by the Company pursuant to Section 3(b),
whichever is earlier.

 

    6 

     

    

 

(e)          
Disability. “Disability” shall mean, at any time the Company or any of its affiliates sponsors a long-term disability
plan for the Company’s employees, “disability” as defined in such long-term disability plan for the purpose of determining
a participant’s eligibility for benefits, provided, however, if the long-term disability plan contains multiple definitions
of disability, “Disability” shall refer to that definition of disability which, if Executive qualified for such disability
benefits, would provide coverage for the longest period of time. The determination of whether Executive has a Disability shall be made
by the person or persons required to make disability determinations under the long-term disability plan. At any time the Company does
not sponsor a long-term disability plan for its employees, “Disability” shall mean Executive’s inability
to perform, with or without reasonable accommodation, the essential functions of Executive’s positions hereunder for a total of
three months during any six-month period as a result of incapacity due to mental or physical illness as determined by a physician selected
by the Company or its insurers and acceptable to Executive or Executive’s legal representative, with such agreement as to acceptability
not to be unreasonably withheld or delayed. Any refusal by Executive to submit to a medical examination for the purpose of determining
Disability shall be deemed to constitute conclusive evidence of Executive’s Disability.

 

(f)            Good
Reason. For the sole purpose of determining Executive’s right to severance payments and benefits as described above,
Executive’s resignation will be with “Good Reason” if Executive resigns within ninety (90) days after any of the
following events, unless Executive consents in writing to the applicable event: (i) a reduction in Executive’s Annual Base
Salary or Target Annual Bonus, (ii) a material decrease in Executive’s authority or areas of responsibility as are
commensurate with Executive’s title or position with the Company, (iii) the relocation of Executive’s primary office to
a location more than twenty-five (25) miles from the Executive’s primary office as of the date of this Agreement or (iv) the
Company’s breach of a material provision of this Agreement. Notwithstanding the foregoing, no Good Reason will have occurred
unless and until: (a) Executive has provided the Company, within sixty (60) days of Executive’s knowledge of the occurrence of
the facts and circumstances underlying the Good Reason event, written notice stating with reasonable specificity the applicable
facts and circumstances underlying such finding of Good Reason; (b) the Company has had an opportunity to cure the same within
thirty (30) days after the receipt of such notice; and (c) the Company shall have failed to so cure within such period.

 

		8.	Parachute Payments.

 

(a)          
Notwithstanding any other provisions of this Agreement or any Company equity plan or agreement, in the event that any payment or
benefit by the Company or otherwise to or for the benefit of Executive, whether paid or payable or distributed or distributable
pursuant to the terms of this Agreement or otherwise (all such payments and benefits, including the payments and benefits under Section
4 hereof, being hereinafter referred to as the “Total Payments”), would be subject (in whole or in part) to
the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then the Total Payments shall be reduced
(in the order provided in Section 8(b)) to the minimum extent necessary to avoid the imposition of the Excise Tax on the
Total Payments, but only if (i) the net amount of such Total Payments, as so reduced (and after subtracting the net amount of
federal, state and local income and employment taxes on such reduced Total Payments and after taking into account the phase out of
itemized deductions and personal exemptions attributable to such reduced Total Payments), is greater than or equal to (ii) the net
amount of such Total Payments without such reduction (but after subtracting the net amount of federal, state and local income and
employment taxes on such Total Payments and the amount of the Excise Tax to which Executive would be subject in respect of such
unreduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to
such unreduced Total Payments).

 

    7 

     

    

 

(b)          
The Total Payments shall be reduced in the following order: (i) reduction on a pro rata basis of any cash severance payments that
are exempt from Section 409A of the Code (“Section 409A”), (ii)   reduction on a pro rata basis of any
non-cash severance payments or benefits that are exempt from Section 409A, (iii) reduction on a pro rata basis of any other payments
or benefits that are exempt from Section 409A, and (iv) reduction of any payments or benefits otherwise payable to Executive on a
pro rata basis or such other manner that complies with Section 409A; provided, in case of clauses (ii), (iii) and (iv), that
reduction of any payments attributable to the acceleration of vesting of Company equity awards shall be first applied to Company
equity awards that would otherwise vest last in time.

 

(c)          
All determinations regarding the application of this Section 8 shall be made by an accounting firm or consulting group with experience
in performing calculations regarding the applicability of Section 280G of the Code and the Excise Tax selected by the Company (the “Independent
Advisors”). For purposes of determinations, no portion of the Total Payments shall be taken into account which, in the opinion
of the Independent Advisors, (i) does not constitute a “parachute payment” within the meaning of Section 280G(b)(2) of the
Code (including by reason of Section 280G(b)(4)(A) of the Code) or (ii) constitutes reasonable compensation for services actually rendered,
within the meaning of Section 280G(b)(4)(B) of the Code, in excess of the “base amount” (as defined in Section 280G(b)(3)
of the Code) allocable to such reasonable compensation. The costs of obtaining such determination and all related fees and expenses (including
related fees and expenses incurred in any later audit) shall be borne by the Company.

 

(d)         
In the event it is later determined that a greater reduction in the Total Payments should have been made to implement the objective
and intent of this Section 8, the excess amount shall be returned promptly by Executive to the Company.

 

		9.	Miscellaneous Provisions.

 

(a)          
Governing Law. This Agreement shall be governed, construed, interpreted and enforced in accordance with its express terms, and
otherwise in accordance with the substantive laws of the State of New York without reference to the principles of conflicts of law of
the State of New York or any other jurisdiction that would result in the application of the laws of a jurisdiction other than the State
of New York, and where applicable, the laws of the United States.

 

(b)         
Validity. The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity
or enforceability of any other provision of this Agreement, which shall remain in full force and effect.

 

(c)          
Notices. Any notice, request, claim, demand, document and other communication hereunder to any Party shall be effective upon receipt
(or refusal of receipt) and shall be in writing and delivered personally or sent by facsimile or certified or registered mail, postage
prepaid, as follows:

 

		(i)	If to the Company, to the General Counsel of the Company at the Company’s headquarters,

 

(ii)          
If to Executive, to the last address that the Company has in its personnel records for Executive, or

 

		(iii)	At any other address as any Party shall have specified by notice in writing to the other Party.

 

    8 

     

    

 

(d)          
Counterparts. This Agreement may be executed in several counterparts, each of which shall be deemed to be an original, but all
of which together will constitute one and the same Agreement. Signatures delivered by facsimile or PDF shall be deemed effective for all
purposes.

 

(e)         
Entire Agreement. The terms of this Agreement, and the Restrictive Covenant Agreement incorporated herein by reference as
set forth in Section 5, are intended by the Parties to be the final expression of their agreement with respect to the subject matter
hereof and supersede all prior understandings and agreements, whether written or oral, including any prior employment offer letter or
employment agreement between Executive and the Company. The Parties further intend that this Agreement shall constitute the complete and
exclusive statement of their terms and that no extrinsic evidence whatsoever may be introduced in any judicial, administrative, or other
legal proceeding to vary the terms of this Agreement.

 

(f)           
Amendments; Waivers. This Agreement may not be modified, amended, or terminated except by an instrument in writing, signed by Executive
and a duly authorized officer of Company. By an instrument in writing similarly executed, Executive or a duly authorized officer of the
Company may waive compliance by the other Party with any specifically identified provision of this Agreement that such other Party was
or is obligated to comply with or perform; provided, however, that such waiver shall not operate as a waiver of, or estoppel
with respect to, any other or subsequent failure. No failure to exercise and no delay in exercising any right, remedy, or power hereunder
will preclude any other or further exercise of any other right, remedy, or power provided herein or by law or in equity.

 

(g)          
Construction. This Agreement shall be deemed drafted equally by both the Parties. Its language shall be construed as a whole and
according to its fair meaning. Any presumption or principle that the language is to be construed against any Party shall not apply. The
headings in this Agreement are only for convenience and are not intended to affect construction or interpretation. Any references to paragraphs,
subparagraphs, sections or subsections are to those parts of this Agreement, unless the context clearly indicates to the contrary. Also,
unless the context clearly indicates to the contrary, (i) the plural includes the singular and the singular includes the plural; (ii)
 “and” and “or” are each used both conjunctively and disjunctively; (iii) “any,” “all,”
 “each,” or “every” means “any and all,” and “each and every”; (iv) “includes”
and “including” are each “without limitation”; (v) “herein,” “hereof,” “hereunder”
and other similar compounds of the word “here” refer to the entire Agreement and not to any particular paragraph, subparagraph,
section or subsection; and (vi) all pronouns and any variations thereof shall be deemed to refer to the masculine, feminine, neuter, singular
or plural as the identity of the entities or persons referred to may require.

 

(h)           Arbitration.
Any controversy, claim or dispute arising out of or relating to this Agreement, shall be settled solely and exclusively by a binding
arbitration process administered by JAMS/Endispute in New York, New York. Such arbitration shall be conducted in accordance with the
then-existing JAMS/Endispute Rules of Practice and Procedure, with the following exceptions if in conflict: (i) one arbitrator who
is a retired judge shall be chosen by JAMS/Endispute; (ii) each Party to the arbitration will pay one-half of the expenses and fees
of the arbitrator, together with other expenses of the arbitration incurred or approved by the arbitrator; and (iii) arbitration may
proceed in the absence of any Party if written notice (pursuant to the JAMS/Endispute rules and regulations) of the proceedings has
been given to such Party. Each Party shall bear its own attorney’s fees and expenses; provided that the arbitrator may assess
the prevailing Party’s fees and costs against the non-prevailing Party as part of the arbitrator’s award. The Parties
agree to abide by all decisions and awards rendered in such proceedings. Such decisions and awards rendered by the arbitrator shall
be final and conclusive. All such controversies, claims or disputes shall be settled in this manner in lieu of any action at law or
equity; provided, however, that nothing in this subsection shall be construed as precluding the bringing of an action for injunctive
relief or specific performance as provided in this Agreement or the Restrictive Covenant Agreement. This dispute resolution process
and any arbitration hereunder shall be confidential and neither any Party nor the neutral arbitrator shall disclose the existence,
contents or results of such process without the prior written consent of all Parties, except where necessary or compelled in a court
to enforce this arbitration provision or an award from such arbitration or otherwise in a legal proceeding. If JAMS/Endispute no
longer exists or is otherwise unavailable, the Parties agree that the American Arbitration Association (“AAA”)
shall administer the arbitration in accordance with its then-existing rules as modified by this subsection. In such event, all
references herein to JAMS/Endispute shall mean AAA. Notwithstanding the foregoing, Executive and the Company each have the right to
resolve any issue or dispute over intellectual property rights by court action instead of arbitration.

 

    9 

     

    

 

(i)           
Enforcement. If any provision of this Agreement is held to be illegal, invalid or unenforceable under present or future
laws effective during the Term, such provision shall be fully severable; this Agreement shall be construed and enforced as if such illegal,
invalid or unenforceable provision had never comprised a portion of this Agreement; and the remaining provisions of this Agreement shall
remain in full force and effect and shall not be affected by the illegal, invalid or unenforceable provision or by its severance from
this Agreement. Furthermore, in lieu of such illegal, invalid or unenforceable provision there shall be added automatically as part of
this Agreement a provision as similar in terms to such illegal, invalid or unenforceable provision as may be possible and be legal, valid
and enforceable.

 

(j)           
Withholding. The Company shall be entitled to withhold from any amounts payable under this Agreement any federal, state, local
or foreign withholding or other taxes or charges which the Company is required to withhold. The Company shall be entitled to rely on the
advice of counsel if any questions as to the amount or requirement of withholding shall arise.

 

		(k)	Section 409A.

 

(i)           
General. The intent of the Parties is that the payments and benefits under this Agreement comply with or be exempt from Section
409A and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith.

 

(ii)            Separation
from Service. Notwithstanding anything in this Agreement to the contrary, any compensation or benefits payable under this
Agreement that is designated under this Agreement as payable upon Executive’s termination of employment shall be payable only
upon Executive’s “separation from service” with the Company within the meaning of Section 409A (a
 “Separation from Service”) and, except as provided below, any such compensation or benefits described in Section
4 shall not be paid, or, in the case of installments, shall not commence payment, until the thirtieth (30th) day following
Executive’s Separation from Service (the “First Payment Date”). Any installment payments that would have
been made to Executive during the thirty (30) day period immediately following Executive’s Separation from Service but for the
preceding sentence shall be paid to Executive on the First Payment Date and the remaining payments shall be made as provided in this
Agreement.

 

(iii)          Specified
Employee. Notwithstanding anything in this Agreement to the contrary, if Executive is deemed by the Company at the time of
Executive’s Separation from Service to be a “specified employee” for purposes of Section 409A, to the extent
delayed commencement of any portion of the benefits to which Executive is entitled under this Agreement is required in order to
avoid a prohibited distribution under Section 409A, such portion of Executive’s benefits shall not be provided to Executive
prior to the earlier of (i) the expiration of the six-month period measured from the date of Executive’s Separation from
Service with the Company or (ii) the date of Executive’s death. Upon the first business day following the expiration of the
applicable Section 409A period, all payments deferred pursuant to the preceding sentence shall be paid in a lump sum to Executive
(or Executive’s estate or beneficiaries), and any remaining payments due to Executive under this Agreement shall be paid as
otherwise provided herein.

 

    10 

     

    

 

(iv)         
Expense Reimbursements. To the extent that any reimbursements under this Agreement are subject to Section 409A, (A) any such reimbursements
payable to Executive shall be paid to Executive no later than December 31 of the year following the year in which the expense was incurred,
(B) Executive shall submit Executive’s reimbursement request promptly following the date the expense is incurred, (C) the amount
of expenses reimbursed in one year shall not affect the amount eligible for reimbursement in any subsequent year, other than medical expenses
referred to in Section 105(b) of the Code, and (D) Executive’s right to reimbursement under this Agreement will not be subject to
liquidation or exchange for another benefit.

 

(v)            Installments. Executive’s
right to receive any installment payments under this Agreement, including without limitation any continuation salary payments that
are payable on Company payroll dates, shall be treated as a right to receive a series of separate payments and, accordingly, each
such installment payment shall at all times be considered a separate and distinct payment as permitted under Section 409A. Except as
otherwise permitted under Section 409A, no payment hereunder shall be accelerated or deferred unless such acceleration or deferral
would not result in additional tax or interest pursuant to Section 409A.

 

		10.	Executive Acknowledgement.

 

Executive acknowledges that Executive has
read and understands this Agreement, is fully aware of its legal effect, has not acted in reliance upon any representations or promises
made by the Company other than those contained in writing herein, and has entered into this Agreement freely based on

Executive’s own judgment.

 

[Signature Page Follows]

 

    11 

     

    

 

IN WITNESS WHEREOF, the Parties have executed this
Agreement on the date and year first above written.

 

	 	IMMUNEERING CORPORATION
	 	 
	 	By:	 /s/ Benjamin Zeskind
	 	 	Name: Benjamin Zeskind
	 	 	Title: President
	 	 
	 	EXECUTIVE
	 	 
	 	/s/ Biren Amin
	 	      Biren Amin

 

[Signature Page to Employment Agreement]

 

     

     

    

 

EXHIBIT A

 

Separation Agreement and Release

 

This Separation Agreement and Release (“Agreement”)
is made by and between Biren Amin (“Executive”) and Immuneering Corporation (the “Company”) (collectively
referred to as the “Parties” or individually referred to as a “Party”). Capitalized terms used but not defined
in this Agreement shall have the meanings set forth in the Employment Agreement (as defined below).

 

WHEREAS, the Parties have previously entered into
that certain Employment Agreement, dated as of _____, 2021 (the “Employment Agreement”) and that certain Employee Proprietary
Information and Inventions Assignment Agreement, dated as of ________, 2021 (the “Restrictive Covenant Agreement”);
and

 

WHEREAS, in connection with Executive’s
termination of employment with the Company or a subsidiary or affiliate of the Company effective ________, 20__, the Parties wish to resolve
any and all disputes, claims, complaints, grievances, charges, actions, petitions, and demands that Executive may have against the Company
and any of the Releasees as defined below, including, but not limited to, any and all claims arising out of or in any way related to Executive’s
employment with or separation from the Company or its subsidiaries or affiliates but, for the avoidance of doubt, nothing herein will
be deemed to release any rights or remedies in connection with Executive’s ownership of vested equity securities of the Company,
vested benefits or Executive’s right to indemnification by the Company or any of its affiliates (collectively, the “Retained
Claims”).

 

NOW, THEREFORE, in consideration of the
severance payments and benefits described in Section 4 of the Employment Agreement, which, pursuant to the Employment Agreement, are conditioned
on Executive’s execution and non-revocation of this Agreement, and in consideration of the mutual promises made herein, the Company
and Executive hereby agree as follows:

 

1.           
Severance Payments and Benefits; Salary and Benefits. The Company agrees to provide Executive with the severance payments
and benefits described in Section [4(b)/4(c)] of the Employment Agreement, payable at the times set forth in, and subject to the terms
and conditions of, the Employment Agreement. In addition, to the extent not already paid, and subject to the terms and conditions of the
Employment Agreement, the Company shall pay or provide to Executive all other payments or benefits described in Section 3(c) of the Employment
Agreement, subject to and in accordance with the terms thereof.

 

2.            
Release of Claims. Executive agrees that, other than with respect to the Retained Claims, the foregoing consideration represents
settlement in full of all outstanding obligations owed to Executive by the Company, any of its direct or indirect subsidiaries and affiliates,
and any of its or their respective current and former officers, directors, equityholders, managers, employees, agents, investors, attorneys,
shareholders, administrators, affiliates, benefit plans, plan administrators, insurers, trustees, divisions, and subsidiaries and predecessor
and successor corporations and assigns (collectively, the “Releasees”). Executive, on Executive’s own behalf
and on behalf of any of Executive’s heirs, family members, executors, agents, and assigns, other than with respect to the Retained
Claims, hereby and forever releases the Releasees from, and agrees not to sue concerning, or in any manner to institute, prosecute, or
pursue, any claim, complaint, charge, duty, obligation, or cause of action relating to any matters of any kind, whether presently known
or unknown, suspected or unsuspected, that Executive may possess against any of the Releasees arising from any omissions, acts, facts,
or damages that have occurred up until and including the date Executive signs this Agreement, including, without limitation:

 

     

     

    

 

(a)            any and all claims
relating to or arising from Executive’s employment or service relationship with the Company or any of its direct or indirect subsidiaries
or affiliates and the termination of that relationship;

 

(b)            any and all claims relating to, or arising
from, Executive’s right to purchase, or actual purchase of any shares of stock or other equity interests of the Company or any of
its affiliates, including, without limitation, any claims for fraud, misrepresentation, breach of fiduciary duty, breach of duty under
applicable state law, and securities fraud under any state or federal law;

 

(c)            any and all claims for wrongful discharge of
employment; termination in violation of public policy; discrimination; harassment; retaliation; breach of contract, both express and implied;
breach of covenant of good faith and fair dealing, both express and implied; promissory estoppel; negligent or intentional infliction
of emotional distress; fraud; negligent or intentional misrepresentation; negligent or intentional interference with contract or prospective
economic advantage; unfair business practices; defamation; libel; slander; negligence; personal injury; assault; battery; invasion of
privacy; false imprisonment; conversion; and disability benefits;

 

(d)            any and all claims for violation of any
federal, state, or municipal statute, including, but not limited to, Title VII of the Civil Rights Act of 1964; the Civil Rights Act of
1991; the Rehabilitation Act of 1973; the Americans with Disabilities Act of 1990; the Equal Pay Act; the Fair Labor Standards Act; the
Fair Credit Reporting Act; the Age Discrimination in Employment Act of 1967; the Older Workers Benefit Protection Act; the Employee Retirement
Income Security Act of 1974; the Worker Adjustment and Retraining Notification Act; the Family and Medical Leave Act; and the Sarbanes-Oxley
Act of 2002;

 

		(e)	any and all claims for violation of the federal or any state constitution;

 

(f)             any and all claims arising out of any other
laws and regulations relating to employment or employment discrimination;

 

(g)            any claim for any loss, cost, damage,
or expense arising out of any dispute over the non-withholding or other tax treatment of any of the proceeds received by Executive as
a result of this Agreement;

 

(h)            any and all claims arising out of the
wage and hour and wage payments laws and regulations of the state or states in which Executive has provided service to the Company or
any of its affiliates; and

 

(i)             any
and all claims for attorneys’ fees and costs.

 

Executive agrees that the release set forth in this section shall be and remain
in effect in all respects as a complete general release as to the matters released. This release does not release claims that cannot
be released as a matter of law, including, but not limited to, Executive’s right to report possible violations of federal law
or regulation to any governmental agency or entity in accordance with the provisions of and rules promulgated under Section 21F of
the Securities Exchange Act of 1934 or Section 806 of the Sarbanes-Oxley Act of 2002, or any other whistleblower protection
provisions of state or federal law or regulation and any right to receive an award for information provided thereunder,
Executive’s right to file a charge with or participate in a charge by the Equal Employment Opportunity Commission, or any
other local, state, or federal administrative body or government agency that is authorized to enforce or administer laws related to
employment, against the Company for discrimination (with the understanding that Executive’s release of claims herein bars
Executive from recovering such monetary relief from the Company or any Releasee for any alleged discriminatory treatment), claims
for unemployment compensation or any state disability insurance benefits pursuant to the terms of applicable state law, claims to
continued participation in certain of the Company’s group benefit plans pursuant to the terms and conditions of COBRA, claims
to any benefit entitlements vested as the date of separation of Executive’s employment pursuant to written terms of any
employee benefit plan of the Company or its affiliates and Executive’s right under applicable law, any Retained Claims and any
claims under this Agreement.

 

    A-2 

     

    

 

3.             Acknowledgment
of Waiver of Claims under ADEA. Executive understands and acknowledges that Executive is waiving and releasing any rights
Executive may have under the Age Discrimination in Employment Act of 1967 (“ADEA”), and that this waiver and
release is knowing and voluntary. Executive understands and agrees that this waiver and release does not apply to any rights or
claims that may arise under the ADEA after the date Executive signs this Agreement. Executive understands and acknowledges that the
consideration given for this waiver and release is in addition to anything of value to which Executive was already entitled.
Executive further understands and acknowledges that Executive has been advised by this writing that: (a) Executive should consult
with an attorney prior to executing this Agreement; (b) Executive has 21 days within which to consider this Agreement, and the
Parties agree that such time period to review this Agreement shall not be extended upon any material or immaterial changes to this
Agreement; (c) Executive has seven days following Executive’s execution of this Agreement to revoke this Agreement pursuant to
written notice to the General Counsel of the Company; (d) this Agreement shall not be effective until after the revocation period
has expired; and (e) nothing in this Agreement prevents or precludes Executive from challenging or seeking a determination in good
faith of the validity of this waiver under the ADEA, nor does it impose any condition precedent, penalties, or costs for doing so,
unless specifically authorized by federal law. In the event Executive signs this Agreement and returns it to the Company in less
than the 21 day period identified above, Executive hereby acknowledges that Executive has freely and voluntarily chosen to waive the
time period allotted for considering this Agreement.

 

		4.	Restrictive Covenants.

 

(a)            Executive’s covenants under the
Restrictive Covenant Agreement are hereby incorporated by reference into this Agreement. Executive acknowledges and agrees that Executive’s
obligations under the Restrictive Covenant Agreement shall remain in full force and effect following the Separation Date in accordance
with the terms thereof.

 

(b)            Executive agrees that Executive shall
not publicly disparage, criticize or defame the Company or its directors, officers, products, services, technology or business. Nothing
in this Section 5(b) will prohibit disclosure of information that is required to be disclosed to enforce the terms of this Agreement or
to comply with applicable law or order of a court or other regulatory body of competent jurisdiction.

 

(c)            Executive represents and warrants that
Executive has returned to the Company all files, memoranda, records and other documents, and any other physical or personal property which
are the property of the Company and which Executive had in Executive’s possession, custody or control.

 

		6.	No Oral Modification. This Agreement may only be amended
in a writing signed by Executive and a duly authorized officer of the Company.

 

    A-3 

     

    

 

7.           
Governing Law; Dispute Resolution. This Agreement shall be subject to the provisions of Sections 9(a), 9(c), and 9(h) of
the Employment Agreement.

 

8.           
Effective Date. Executive has seven days after Executive signs this Agreement to revoke it and this Agreement will become
effective on the day immediately following the seventh day after Executive signed this Agreement (the “Effective Date”).

 

9.             Voluntary
Execution of Agreement. Executive understands and agrees that Executive executed this Agreement voluntarily, without any duress
or undue influence on the part or behalf of the Company or any third party, with the full intent of releasing all of
Executive’s claims against the Company and any of the other Releasees. Executive acknowledges that: (a) Executive has read
this Agreement; (b) Executive has not relied upon any representations or statements made by the Company that are not specifically
set forth in this Agreement; (c) Executive has been represented in the preparation, negotiation, and execution of this Agreement by
legal counsel of Executive’s own choice or has elected not to retain legal counsel; (d) Executive understands the terms and
consequences of this Agreement and of the releases it contains; and (e) Executive is fully aware of the legal and binding effect of
this Agreement.

 

[Signature Page Follows]

 

    A-4 

     

    

 

IN WITNESS WHEREOF, the Parties have executed
this Agreement on the respective dates set forth below.

 

	 	 	EXECUTIVE
	Dated:	 	 	
	 	 	Biren Amin
	 	 	 
	 	 	IMMUNEERING CORPORATION
	 	 	 
	Dated:	 	 	By:	 
	 	 	 	Name:
	 	 	 	Title:

 

    A-5 

     

    

 

EXHIBIT B

 

Restrictive Covenant Agreement

 

[attached]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00331-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00331-of-00352.parquet"}]]